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AF asymmetry factor 
AUC area under curve 
bar atmosphere = 105 pascal (Pa) 
BGE background electrolyte 
CD cyclodextrin 
CE capillary electrophoresis 
CGE capillary gel electrophoresis 
CIEF capillary isoelectric focusing 
cm centimeter = 10-2 m 
CM-β-CD carboxymethylated-β-cyclodextrin 
CZE capillary zone electrophoresis 
DAD diode-array detector 
DNS dansyl 
dp particle diameter 
EOF electro-osmotic flow    
F flow rate 
FSCE free solution capillary electrophoresis 
HETP height equivalent to theoretical plate 
HP-β-CD hydroxypropyl-β-cyclodextrin 
HPLC high performance liquid chromatography 
HS-β-CD high sulphated-β-cyclodextrin 
ICH international conference on harmonisation 
I.D. internal diameter of the column 
LC liquid chromatography 
LOD limit of detection 
LOQ limit of quantitation 
m meter 
µ micro = 10-6 meter 
MEKC miceller electrokinetic capillary chromatography 
µep electrophoretic mobility 
min minute 
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mM millimolar = 10-3 Molar 
nl nanoliter = 10-9 l 
PEEK poly(ether ethyl ketone) 
pKa ionization constant 
RP reversed-phase 
RP-HPLC reversed-phase high performance liquid chromatography 
RPC reversed phase chromatography 
RSD relative standard deviation 
s second 
SFC supercritical-fluid chromatography 
S/N ratio signal-to-noise ratio 
UPLC ultra performance liquid chromatography 
UV/Vis  ultraviolet/visible 
V volt 
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k retention factor (k = tR-to/to) 
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N plate number 
r radius 
Rs resolution value 
R
2
 coefficient of determination 
T absolute temperature 
t time 
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tm migration time 
tR retention time 
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1 Introduction  
1.1 High Performance Liquid Chromatography (HPLC)  
1.1.1 Introduction to HPLC 
High performance liquid chromatography (HPLC) has become one of the most 
important and fastest growing techniques in analytical laboratory.  The basic theory 
behind high performance liquid chromatography is not new, but it was not until 
around 1969 that HPLC was developed in its present form. This development 
introduced the effective use of a small diameter packing material and columns, which 
allowed the chromatographer to perform separations faster and with greater 
resolution than had previously been attainable. The basic of separation in HPLC 
involves partitioning of the analyte molecule between the liquid mobile phase and the 
solid stationary phase [1].   
1.1.2 HPLC components 
The essential components of a complete HPLC system are solvent delivery system 
(pump), detector, fixed volume injector loop or autosampler, solvent reservoirs, 
packed column, data system and recorder. A schematic of a simplified HPLC system 
is shown in Figure 1. 
1.1.2.1 Column 
The column is probably the heart of HPLC system. The development of this column 
technology leads to the evolution of the HPLC instrumentation systems used today. 
The conventionally used HPLC columns are particle packed columns. The key of 
column selection when previous separation is not available resides in knowing the 
chemistry of the sample. Columns should never be dry. A dry column will eventually 
have voids because the packing will shrink away from the wall, which would result in 
band broadening. Before running a sample in HPLC the column should be 
equilibrated. Usually column equilibrium is achieved after passage of 10 – 20 column 
volumes of the new mobile phase through the column. Insufficient column equilibrium 
usually leads to retention difference [2].  
1.1.2.2 Pump 
The solvent delivery system or as it is commonly called the pump includes two major 
types, constant volume or flow and constant pressure. Constant volume pumps are 
mechanically driven systems, most commonly using screw driven syringes or 
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reciprocating pistons. On the other hand, constant pressure pumps are driven or 
controlled by gas pressure [3]. 
 
 
 
 
 
Figure 1: Schematic diagram of a basic HPLC system. The parts are (1) 
reservoir, (2) pump, (3) autosampler, (4) injection valve, (5) column, (6) detector 
and (7) data system. 
 
1.1.2.3 Injector or Autosampler  
Samples are usually introduced by syringe injection via a manual injector into the 
mobile phase stream or by the use of an autosampler. The important aspects in 
sample introduction are precise and reproducible injections. This is especially 
important with quantitative analysis where the reproducibility of the peak response is 
dependant on the precision of the sample introduction. Direct syringe injection 
through a manual injector was the first popular method of sample introduction. As 
HPLC instrumentation evolved, many autosampler techniques were applied so that 
sample introduction has become more precise and rapid [4].  
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1.1.2.4 Detector   
HPLC detectors include ultraviolet-visible, fluorescence, electrochemical, refracto-
meter, mass spectrometer and others. The UV visible absorption detector is the most 
widely used detector in liquid chromatography, since most organic compounds show 
some useful absorption in the UV region. This detector is fairly universal in 
application, although sensitivity depends on how strongly the sample absorbs light at 
a particular wavelength [5].  
1.1.2.5 Solvent reservoir 
Different containers are used as a solvent delivery system reservoir. The best 
material from which the containers are made is glass.  Plastic containers are not 
recommended as it leads to plasticizer leaching. The container should be covered to 
prevent solvent evaporation. The tubing from the reservoir can be made of stainless 
steel or Teflon, and both are satisfactory [3]. 
1.1.2.6 Data handling and analysis 
Data handling in HPLC is as important to the success of any experiment or analysis 
as any other components in the system. It is part of good HPLC techniques to 
properly label and document the analytical results. The advanced computer 
softwares used now in data handling and analysis allow easy recording and storage 
of all chromatographic data [6].  
1.1.2.7 Calculation of peak parameters in HPLC 
Chromatographic efficiency, expressed as the number of theoretical plates (N) was 
calculated based on the equation N = 16 (tR/w)
2, where N = number of theoretical 
plates,  tR = retention time, w = peak width at the base. Parameters are calculated as 
shown in Figure 2. Resolution was calculated using the equation 
Rs = 2 (tR2 - tR1/w2 + w1). Asymmetry factor (AF) = A/B at 10% of peak height (A and B 
are the two half widths at each side of the peak centre) as shown in Figure 3. 
1.1.3 Types of partition high performance liquid chromatography  
1.1.3.1 Normal phase chromatography  
Normal phase chromatography is characterized by the use of an inorganic adsorbent 
or chemically bonded stationary phase with polar functional groups and a non-
aqueous mobile phase. This phase is consisting of one or more non-polar organic 
solvents. 
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Figure 2:  Representative diagram showing how peak parameters were 
calculated. 
 
The retention of a solute is essentially determined by the balance of interactions it 
experiences in the mobile phase and its competition with mobile phase molecules for 
adsorption sites at the surface of the stationary phase [7].  
1.1.3.2 Reversed phase liquid chromatography (RPLC) 
The popularity of reversed phase liquid chromatography is easily explained by its 
unmatched simplicity, versatility and scope. Neutral and ionic analytes can be 
separated simultaneously. Retention in RPLC is believed to occur through non-
specific hydrophobic interaction of the solute with the stationary phase. The near 
universal application of RPLC stems from the fact that almost all organic compounds 
have hydrophobic regions in their structure and are capable of interacting with the 
stationary phase. 
 
 
w 
tR 
w1/2 
h1/2 
h 
Area 
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Figure 3: Representative diagram showing the method used for calculating 
peak asymmetry factor as recommended by USP. The asymmetry factor (AF) is 
equal to the ratio A/B. 
 
A decrease in the polarity of the mobile phase leads to a decrease in retention. It is 
also generally observed in RPLC that branched chain compounds are retained to a 
lesser extent than their straight chain analogues and that unsaturated compounds 
are eluted before their fully saturated analogs [1]. 
A wide variety of RP-HPLC columns are available. Most columns are silica based. 
Silica offers good mechanical stability. A typical stationary phase is formed by 
chemically bonding a long-chain hydrocarbon group to porous silica. Typical ligands 
are n-octadecyl (C18), n-octayl (C8), n-butyl (C4), diphenyl, and cyano propyl [8].  
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1.1.3.2.1 Parameters affecting separation  
Separation in reversed phase chromatography is affected by stationary phase type 
and column length. It is also affected by organic solvent type and percentage in the 
mobile phase and by mobile phase pH. Flow rate could also affect separation in 
reversed phase chromatography; however it is usually limited by the developed 
backpressure. Moreover temperature of the column also has an effect on separation. 
Parameters affecting separation in reversed phase chromatography are shown 
schematically in Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Parameters affecting separation in reversed phase chromatography. 
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1.1.3.2.2 Silica-based columns for RP-HPLC 
The first introduced materials were based on irregular shaped silica particles, which 
had been bonded with a range of alkyl-bonded silanes having a carbon side chain. 
There are three common chain lengths, C4, C8, and C18. The octadecylsilyl (C18H37-, 
ODS) alkyl chain, rapidly became the most popular. The next development was the 
use of end capping, where a smaller reagent as trimethylsilyl chloride is used to cap 
the free silanol groups of the silica surface [9].   
Nowadays, columns are packed with spherical silica particles.  The beads or particles 
are generally characterized by particle size.  Particle sizes generally range between 3 
and 50 µm, with 3 to 5 µm particles being the most popular for analytical columns.  
Larger particles will generate less system pressure and smaller particles will generate 
more pressure. However, the smaller particles generally give higher separation 
efficiencies. Column dimensions are described by the column length, either in cm or 
mm, and the columns inside diameter in mm. The size of the column is determined by 
the particle size of the stationary phase. For example, 3 µm particles are packed in 
shorter column lengths because a 250 mm column would generate too much back 
pressure for a typical HPLC system. Also, because the 3 micron particles are very 
efficient, a shorter column probably has enough theoretical plates for the required 
separation. The typical analytical column inside diameter is 4.6 mm. 
1.1.3.2.3 Isocratic vs. gradient elution  
When the composition of the mobile phase is held constant, the practice is called 
isocratic elution. In contrast, in gradient elution, which is often preferred for 
separation of complex mixtures, the composition of the mobile phase is changed 
stepwise or linearly by mixing two or more solvents. The use of binary, ternary, and 
quaternary solvent gradients is fairly common [6]. The usual reason for choosing 
gradient elution is that the sample has a wide retention range were no isocratic 
condition result in 0.5 < k < 20 for all bands of interest. 
Samples of large molecules especially biological and those containing late 
interferences that can either foul the column or overlap with subsequent 
chromatograms also sometimes require gradient elution. An initial gradient elution 
run is often the best starting point for HPLC method development even when a final 
isocratic method is possible.  
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Many disadvantages have been reported for gradient elution. First, gradient 
equipment is not available in some laboratory. Furthermore, it cannot be used with 
some HPLC detectors e.g. refractive detector and do not always transfers well 
because difference in equipment can cause change in separation. Baseline problems 
are more common with gradient elution. In addition gradient elution takes longer 
runtime because of the need for column equilibrium after each run. Nowadays, there 
are many types of software for computer assisted method development. However, 
they still face many problems. For example, it needs an equipped HPLC system to 
perform these experiments automatically. Furthermore, failure of good column 
equilibrium creates a problem when a computer is used to predict retention and 
separation on the basis of prior runs. For these reasons and others the step by step 
approach is more favourable which allows interpreting the chromatograms from prior 
runs before choosing conditions for the next runs. 
1.1.3.2.4 Classical method development strategy for RP-HPLC  
The main steps for method development are shown in Chart 1. Before the 
development of a method the goals should be clearly defined. The goal could be 
assay of an active substance, so that the separation of other substances is not 
necessary. When the goal is the assay of impurities or other degradation products, a 
high detection sensitivity and resolution of all sample components should be planned.  
The goal could also be isolation or quantitation of the sample components. 
Furthermore, certain desires could be taken in account when developing a new 
method such as a short analysis time. The next step is the determination of sample 
information. In this context method development for regular neutral or ionic (acidic, 
basic, amphoteric or organic salt) samples will be discussed. Special samples as 
enantiomers which require chiral conditions will be out of this investigation.  Also very 
hydrophilic samples may not have sufficient retention in RPLC even with mobile 
phase containing little or no organic solvent so that normal phase separation is 
required. One should try to collect as much as possible of sample information. This 
includes the number of compounds in the sample, the chemical structure of all or 
some of them, the molecular weight of the compounds, the pKa values of the 
individual compounds, UV spectra, concentration range of the compounds and the 
sample solubility.  
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Chart 1: Main steps for method development in reversed phase HPLC.  
Choice of initial separation conditions 
(column type, mobile phase, flow type, detection wavelength) 
Development of the best separation conditions 
(acceptable baseline separation) 
 
Optimization of separation conditions  
(resolution, analysis time, quantitation limit, solvent consumption) 
 
Method validation  
 
Detector choice 
 
Sample Information 
 
Method development goal 
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Physicochemical properties of the sample components help to select proper buffer 
system and to guess about a suitable starting mobile phase based on hydrophobicity. 
UV spectra help to determine the maximum wavelength for detection. However, if no 
information is available (unknown sample) one could initially detect at 210 nm and 
afterwards adjust the detection wavelength depending on spectra provided by a 
diode-array detector (DAD). Accordingly it is useful but not essential to know the 
chemical structure and properties of the various sample compounds which helps in 
sample pre-treatment and detection. In principle, method development for any regular 
sample can be carried out in the same way regardless of whether the sample 
composition is known or standards are available. The composition of sample solvent 
should preferably be the mobile phase or a solution of lower elution strength to 
minimize baseline upset, decrease peak width and get better resolution.  
Sample volume and mass are better to be small to avoid column overload. Even 
when a small volume is injected it is possible because of the mass of the sample to 
overload the column and so to broaden and change peak shape. This happens 
because the stationary phase can become saturated with the sample.  
Especially sample volumes and masses of basic compounds should be small on 
silica columns to avoid band broadening and tailing as a result of silanol interactions. 
Increasing the sample size decreases N, tR and Rs and gives broad peaks. However, 
the largest possible sample may be needed to increase detection sensitivity. One 
should be sure that the detector will detect all sample components of interest. The 
diode-array detector (DAD) is the first choice detector as it is applicable for most 
samples either directly or after derivatization. UV spectra can be found in literature or 
estimated from chemical structure or measured directly using UV spectrophotometer 
if pure compounds are available. However they can also be obtained during HPLC 
separation if DAD is available to give the UV scan for pure peaks.  In such case, one 
could start the HPLC separation at 210 nm at which most of the compounds should 
have certain absorption. Another advantage of using a DAD detector instead of a 
simple UV-visible one is the ability to check peak purity and even peak identity if one 
has a standard UV spectra library. If UV response is inadequate one should use 
other detectors as fluorescence or electrochemical ones or derivatize the sample. 
The separation mechanism involves sample partition between a polar mobile phase 
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(water-organic) and a non-polar stationary phase. The results are different retentions 
of sample components according to the hydrophobicity of the sample. The less 
hydrophobic components elute first. An increase of solvent strength will decrease 
mobile phase polarity and so decrease the retention of compounds. The development 
strategy involves the start with a high percentage (not more than 95%, usually 80%) 
of organic modifier (e.g. acetonitrile or methanol) followed by successive runs with a 
10 or 20% decrease of organic modifier in each run (down to not less than 5%) until 
all the peaks of interest are resolved within an acceptable run time and with the best 
possible resolution.  
Generally one should not use more than 95% water in the mobile phase because the 
bonded phase can collapse if too much water is present, thus, it would change the 
retention characteristic of the column. On the other hand, higher percentage of 
organic modifier could affect the solubility of the buffer in the mobile phase. The 
change of solvent type (e.g. 40% ACN by 40% MeOH) or using a mixture of two 
organic solvents (e.g. 20% ACN + 20% MeOH) will probably have a greater effect on 
selectivity than changing solvent strength (solvent type selectivity). The use of amine 
modifier will improve the peak shape of basic samples when working at high pH due 
to blockage of ionized silanol by amines. The aqueous part of the mobile phase 
should be buffered at a certain pH especially for ionic samples. Changing the pH of 
the aqueous part of the mobile phase is another possible step to achieve good 
resolution. Most pH related changes occur within ± 1.5 unit of the pKa value, outside 
this range the compound is almost completely ionized or non-ionized, so the retention 
does not change significantly with pH change. In RP retention increases when the 
compound becomes non-ionized. Most acidic drugs have pKa 4 - 5 and basic pKa 
8  - 11. One should note that some acidic or basic compounds undergo a change in 
absorbance as pH is varied so that the band size changes. As the compounds 
become more ionized the retention time decreases e.g. for acidic compounds the 
retention time decreases at a high pH value of the mobile phase. Under non-ionizable 
condition the compound solubility in water deceases, so requiring the use of higher 
percentage of organic modifier in the mobile phase. An exception is given by sample 
matrices tending to precipitate at this pH (at which the compounds are non-ionized). 
In this case one should work under ionizable conditions to insure reproducible results 
not only for ionic samples, but also for neutral ones, because they may contain ionic 
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species. It is better to measure the pH of the aqueous part of the mobile phase 
before mixing with the organic solvent even though the solution ionization property 
may change after mixing with organic solvent. This is because electrode response for 
a mixture of aqueous and organic mobile phase tends to drift and so it is more 
difficult to get reproducible result. In silica based columns basic compounds can 
interact with ionisable silanols groups leading to increased retention, tailing and 
column to column irreproducibility.  Protonated base (BH+) in sample exchange with 
sodium, potassium, or other cations that are attached to ionized silica. All silica based 
columns contain accessible silanols, but their effect on sample retention can be 
reduced by one of the following ways: First, the use a low pH mobile phase 
(2 < pH < 3.5) to minimize the number of ionized silanols. Second, by working at a 
high pH at which basic compounds are not protonated (but this interferes with the fact 
that silica based columns are not completely stable under high pH values).  Third, the 
use of high concentration phosphate buffer; high buffer concentration may be 
valuable as buffer cations will compete with sample cations to the ionized silica. 
Fourth, use low sample amount for basic compounds. When mixing aqueous and 
organic modifier parts of the mobile phase, one should keep in mind several facts.  A 
methanol-water mobile phase gives higher solubility for buffers (e.g. phosphate 
buffer), than acetonitrile-water. Buffers with potassium salts are more soluble than 
buffers with sodium salts. Citrate buffer show a high UV absorbance so limiting the 
UV detection to wavelengths above 230 nm. Phosphate buffers control pH in the 
range of 2.1 - 3.1 and 6.2 - 8.2 while acetate buffers work in the range 3.8 – 5.8. Care 
should be taken to avoid precipitation of the buffer at high percentage of organic 
modifier. This may require low buffer concentration (5 or 10 mM) or more soluble 
buffers. The separation achieved in the first runs usually will be less than adequate. 
Improving the separation in term of resolution or analysis time should be done to 
obtain a good developed method. In addition, further optimization of the resolution, 
analysis time and quantitation limit may be required. The final optimized method 
should then be validated according to the ICH requirements and valid 
pharmacopoeias [10]. 
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1.1.4 Fast HPLC analysis  
1.1.4.1 Definition  
There is no clear definition for fast analysis. The term fast HPLC is a relative one. 
Fast analysis refers to decreasing the analysis time of a method. Analysis time by 
itself is sometimes a poor measurement of chromatographic parameters; rather the 
important parameter is the number of compounds separated per unit time. For 
example a 10 compounds running in ten minutes is more time efficient than a 2 
compounds run in 10 minutes. Nevertheless, it should be noted that the terms “fast 
LC”, “high speed HPLC”, “fast HPLC” and “ultra-fast HPLC” are common place in the 
literature without a formal definition.  
1.1.4.2 Factors affecting fast HPLC analysis  
Factors affecting HPLC analysis are best described in Table 1. Several approaches 
have commonly been used for fast chromatography during the last decade. In 
general short column, high temperature, high flow rates all should lead to a faster 
HPLC analysis. Each of these parameters is interrelated with the dependant 
parameters of analysis time, column backpressure and column efficiency. Table 1 
lists the relationship among these parameters [11]. However, the effect of 
temperature on analysis time and efficiency is sometimes variable and unpredictable. 
 
Table 1: Relationship between the independent parameters: column length, 
flow rate, particle size and column temperature to the dependant parameters of 
analysis time, column backpressure and column efficiency.* 
 
 
 
Column 
Length 
(L) 
Flow 
Rate 
(F) 
Particle 
Diameter 
 (dp) 
Column 
Temperature 
(T) 
Analysis time α  L α  1/ F indirectly 
related 
α  1/Tx 
Backpressure α  L α  F α  1/( dp)
2 α  1/T 
Efficiency  α  L 
by Van 
Deemter 
α  1/ dp α  T 
 
*α means directly proportional  
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1.1.4.2.1 Short columns 
 The use of a short column reduces separation time. However, resolution will be 
reduced due to reduction of plate numbers at the same time. Half the column length 
means half the run time and half the number of plates. In general, column length is 
directly proportional to analyte retention time, column efficiency and backpressure. 
Reduction of column length is acceptable as long as column efficiency remains 
sufficient for separation. The use of small particles with short columns will 
compensate for reduced efficiency but will be limited again by the backpressure [12]. 
1.1.4.2.2 Increasing the flow rate  
Increasing the flow rate is another way for reducing run time. Flow rate is inversely 
proportional to analysis time, so doubling the flow rate will result in halving the 
analysis time.  An optimum flow rate has been established for common column 
diameters. These optimum flow rates correspond to (more or less) the highest 
column efficiency according to the Van Deemter plot. Doubling the flow rate saves as 
much time as using a column with half the plate length. Keeping in mind that, 
increasing flow rate also means less reduction of plate number than reducing column 
length [12].  
Unfortunately, flow rate is also proportional to the pressure drop across the column, 
measured as system pressure or column backpressure. Most fast analyses operate 
above the optimum flow rate, typically at the highest flow rate possible within allowed 
column and system pressures.  
1.1.4.2.3 Small particles  
Columns with small particle sizes (e.g. 2 µm) will lead to a fast analysis due to the 
superior efficiency. However, this is very challenging as this approach result in high 
pressure and the columns are more likely to be blocked [12]. 
1.1.4.2.4 High temperature 
High temperature is beneficial in at least three aspects. First, an increase in column 
temperature reduces the viscosity of the mobile phase and therefore the column 
backpressure, permitting faster flow rates. Second, an increase in column 
temperature deceases band spacing and so increases resolution between adjacent 
peaks. Third, an increase in column temperature enhances analyte mass transfer, 
increasing efficiency at faster flow rates. The use of increased column temperature is 
limited by the thermal stability of the analyte, the thermal stability of the stationary 
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phase and the boiling point of the mobile phase.  Even with increasing the 
temperature, column backpressure remains the limiting factor. Therefore the 
traditional approaches to fast HPLC analysis are inherently restricted by column 
backpressure. 
1.1.4.3 New trends for fast LC analysis 
Nowadays, there is a competition between two means for fast LC analysis, namely, 
HPLC with monolithic phases and small particle phases used in ultra performance 
liquid chromatography (UPLC™). With both phase types a substantially higher 
column efficiency, analysis speed and sensitivity can be achieved. With UPLC™ this 
is achieved particularly by the use of small particles in the stationary phases. 
However, the use of small sub-2µm particles requires the use of ultra high pressure 
(approximately 1400 bar) demanding special high quality equipment to cope with the 
high pressures. While for UPLC™ many phases are already commercially available, 
the selection of available monolithic phases is still limited at present to standard 
materials such as RP-18 and RP-8. However, these phases do have a substantially 
higher permeability to build a much lower backpressure in comparison to the small 
particle phases used in UPLC. Therefore monolithic phases can be used with 
standard HPLC instruments. 
1.1.4.3.1 Monolithic silica columns 
1.1.4.3.1.1 Overview about monolithic silica columns 
Monolithic silica columns were first introduced in 1991 by Minakuchi and Soga [13]. 
The preparation of these silica rod materials involved a sol-gel process using highly 
pure silica. The formed silica rod is then encased in poly ether ethyl ketone (PEEK) 
shrink-warp tubing, which prevents void formation. The obtained highly porous 
skeleton is characterized by a bimodal pore structure consisting of large macropores 
(diameter 2 µm), and mesopores (13 nm in diameter). The large macropores are 
responsible for a low flow resistance and therefore allow for the application of high 
eluent flow rates, while the small pores ensure sufficient surface area (300 m2/g 
approximately) for separation efficiency. Monolithic columns also have a significantly 
higher total porosity after octadecylsilylation than conventional particulate columns, 
over 80% vs. ca 65%, respectively [14]. However, due to the fact that the density of 
monolithic columns is much lower, the loadability of a conventional column of the 
same size is much higher. The main parameters for a monolithic silica HPLC column 
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are summarized in Table 2 [15]. Till now the stationary phase availability of monolithic 
columns is limited to normal silica, C8 and C18. Furthermore, because of the 
significant shrinkage during the formation of the skeleton, it is difficult to prepare 
straight rods longer than about 15 cm, which limits the length of the final columns. 
However, it is possible to enhance the separation efficiency by coupling several 
monolithic columns together. Nowadays about 450 papers were published describing 
the use of monolithic columns in various fields. This includes drug analysis [16-19], 
food and environmental analysis [20, 21] and bio-analysis [22-24]. There have been 
many investigations into the feasibility and parameters during method transfer from 
traditional LC columns to monolithic columns [25-29]. 
Table 2: Specification for a Chromolith Performance HPLC column. 
Silica type  High purity (99.99%) 
Particle size Monolithic 
Macropore size  2 µm 
Mesopore size 13 nm 
Surface area 300 m2/g 
Total porosity  > 80% 
Surface modification  RP-18 endcapped 
pH range  2.0 - 7.5 
Column cladding material  PEEK [poly(ether ethyl ketone)] 
 
However, the number of developed methods using monolithic columns is much 
smaller than that using particle packed columns. Till now they are not mentioned in 
official methods of any pharmacopoeia. Furthermore, the transferability of analytical 
methods from conventional to monolithic columns and the precision of such columns 
are still under discussion.  
1.1.4.3.1.2 Particle packed vs. monolithic silica columns  
The use of conventional particle packed HPLC columns containing the classic 3 or 5 
µm small silica particles often results in high back pressure. This high back pressure 
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may damage both the column and the HPLC system; therefore, classic HPLC 
columns have limited length and a limited number of theoretical plates. Increasing the 
plate count by using 2 or sub 2 µm particle size have been tried, but this results in 
unacceptable backpressure when normal HPLC instruments are used. Scientists 
wish to speed up the entire separation process and accelerate the analysis without 
much affecting the resolution or facing high system backpressure. High throughput 
analysis has become one of the most important issues in the high performance liquid 
chromatography. Laboratory automation of HPLC systems has come a long way 
toward improving sample throughput by enabling 24 hours a day operation. The 
systems however are still limited by the separation technology itself, that is, the 
separation column available. Monolithic silica columns are claimed to provide 
excellent separations in a fraction of time that a standard particulate (particle-packed) 
column will take, because they are made from high porous monolithic rods (Figure 5) 
with a bimodal pore structure. 
 
 
 
 
 
 
Figure 5: Monolithic porous silica bodies shaped as rod [30]. 
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The column is no longer packed with small particles but consists of a single piece of 
high purity polymeric silica gel. High flow rates could be used with monolithic columns 
due to the high porosity of the column provided mainly with macropores. Besides, 
high efficiency is ensured by the mesopores that provide very large surface area for 
separation (Figure 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
C 
B 
Figure 6:  Monolithic Silica A, Macropores B, and Mesopores C [15]. 
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The difference between monolithic and conventional particle-packed columns is 
shown in Figure 7.  
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Representative conventional particle-packed vs. monolithic silica 
HPLC columns [31]. 
Conventional Silica "Particle-Based"   
   High flow resistance: 
Limits ability to shorten run times  
 High backpressure: 
Reduces life of pumps, seals, and column    
Monolithic porous silica rod  
  High flow rates: 
Significantly shorter run times  
          Low backpressures: 
Less stress on system and column  
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Furthermore, the separation efficiency of monolithic columns does not decrease 
significantly when the flow rate is increased, as is the case with particulate columns. 
Accordingly, it is possible to operate monolithic columns at high flow rates with 
minimal loss of peak resolution. It is also possible to connect monolithic columns 
together using a special column coupler to produce a column with high plate count at 
low backpressure for complex separation (Figure 8). High resistance to blockage and 
long column lifetime are also advantages of high porosity. Despite these promising 
characters more time is still needed to improve its applicability to official use and to 
evaluate result repeatability and batch to batch reproducibility and method transfer for 
different pharmaceutical compounds, in addition to method development using them 
[32]. 
 
 
 
 
 
 
 
 
 
Figure 8: Coupling of two Chromolith Performance RP-18e HPLC columns 
using the special monolithic column coupler [15]. 
 
1.1.4.3.1.3 Commercially available monolithic HPLC columns  
The different types and dimensions of monolithic silica HPLC columns provided by  
Merck are summarized in Table 3 [15]. The trade name “Chromolith” indicates a 
monolithic material. The same types and dimensions are also available by 
Phenomenex Company under the trade name “Onyx” [31]. 
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Table 3: Monolithic silica columns produced by Merck Company. 
Column Description Length Internal diameter 
Capillary columns 
Chromolith CapRodTM 150 - 0.1 mm RP-18 
endcapped 
150 mm 0.1 mm 
Analytical columns 
Chromolith Performance 100 - 4.6 mm RP-18 
endcapped 
100 mm 4.6 mm 
Chromolith SpeedROD 50 - 4.6 mm RP-18 
endcapped 
50 mm 4.6 mm 
Chromolith Flash 25-4.6 mm RP-18 endcapped 25 mm 4.6 mm 
Chromolith Performance 100 - 4.6 mm RP-8 
endcapped 
100 mm 4.6 mm 
Chromolith Performance 100 - 4.6 mm Si 100 mm 4.6 mm 
Chromolith Column Coupler   
Chromolith Validation Kit RP.18E 
(3 columns from different batches) 
100 mm 4.6 mm 
Guard columns 
Chromolith RP-18 endcapped Guard column 
5 - 4.6 mm 
5 mm 
 
 
4.6 mm 
Chromolith RP-18 endcapped Guard column 
10 - 4.6 mm 
10 mm 4.6mm 
Semi-preparative and preparative columns 
Chromolith SemiPrep 100 - 10 mm RP-18 endcapped 100 mm 10 mm 
Chromolith prep 100 - 25 mm Si 100 mm 25 mm 
Chromolith prep 100 - 25 mm RP-18 endcapped 100 mm 25 mm 
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1.2 Capillary electrophoresis  
Capillary electrophoresis is a family of related separation techniques that use narrow-
bore fused silica capillaries to separate a complex array of large and small 
molecules. The variations include separation based on size and charge differences 
between analytes (termed Capillary Zone Electrophoresis, CZE, or Free Solution 
Capillary Electrophoresis, FSCE), separation of neutral compounds using surfactant 
micelles (Micellar Electrokinetic Chromatography, MEKC) sieving of solutes through a 
gel network (Capillary Gel Electrophoresis, CGE), and separation of zwitterionic 
solutes within a pH gradient (Capillary Isoelectric Focusing, CIEF). CZE and MEKC 
are the most frequently used separation techniques in pharmaceutical analysis. CGE 
and CIEF are of importance for the separation of biomolecules such as DNA and 
proteins, respectively and are of increasingly importance as development of 
biotechnology derived drugs becoming more frequent [33]. 
1.2.1 CE instrument 
The basic instrumental configuration for CE is relatively simple. All that is required is 
a fused-silica capillary with a narrow bore (typically 25 - 100µm) and with an optical 
detection window, a controllable high voltage power supply, a two electrodes 
assembly, two buffer reservoirs, and a detector e.g. an ultraviolet (UV) one. The ends 
of the capillary are placed in the buffer reservoirs and the optical detection window is 
aligned with the detector. After filling the capillary with buffer, the sample is injected 
by pressure or electrokinetically. Finally the selected voltage is applied to run the 
buffer and analytes. A simplified diagram of a CE instrument is illustrated in Figure 9.  
1.2.2 Capillary zone electrophoresis 
Capillary zone electrophoresis (CZE), also known as free solution capillary 
electrophoresis, is the simplest form of CE. The separation mechanism is based on 
differences in the charge-to-mass ratio. The homogenity of the buffer solution and the 
constant field strength throughout the length of the capillary are important aspects in 
CZE. Capillaries are typically in the range of 25 - 100 µm inner diameter and 0.2 to 
1.0 m in length. The applied potential is typically 10 to 30 kV. Due to the electro-
osmotic flow sample components migrate towards the negative electrode. A small 
volume of sample (typically about 10 nl) is injected at the positive end (anode) of the 
capillary and the separated components are detected near the negative end 
(cathode) of the capillary. CE detection includes absorbance, fluorescence, 
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electrochemical, and mass spectrometer detectors [34]. Following injection and 
application of voltage, the components of a sample mixture separated into discrete 
zones as shown in Figure 10.  
1.2.2.1 Electro-osmotic flow 
The surface of the silicate glass capillary contains negatively-charged silanol 
functional groups (at pH > 2) that attract positively-charged counter ions. The 
positively-charged ions migrate towards the negative electrode and carry solvent 
molecules in the same direction. 
 
 
 
 
 
Figure 9: Schematic diagram of a basic CE system.  
 
 
sample 
injection 
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Figure 10: Separation of charged species by capillary zone electrophoresis. 
This overall solvent movement is called electro-osmotic flow (Figure 11). During a 
separation, uncharged molecules move at the same velocity as the electro-osmotic 
flow. Positively-charged ions move faster and negatively-charged ions move slower. 
At high pH, the EOF is large and at low pH it is very small. This is related to the 
degree of silanol group ionization on the silica of the capillary surface (Figure 12). 
When applying a pressure driven system such as in liquid chromatography, the 
frictional forces at the liquid solid interface result in a laminar or parabolic flow 
profiles. As a consequence of parabolic flow, a cross sectional flow gradient occurs in 
the tube resulting in a flow velocity that is highest in the middle of the tube and 
approaches zero at the tubing wall.  
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Figure 11: Electro-osmotic flow inside capillary. 
 
This velocity gradient results in substantial band broadening. In electrically driven 
systems as CE, the driving force of the EOF is uniformly distributed along the entire 
diameter of the capillary. As a result the flow velocity is uniform across the entire 
tubing diameter except very close to the wall where the velocity again approaches 
zero (Figure 13) [34]. 
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Figure 12:  Effect of pH on the electro-osmotic flow inside the capillary. 
 
 
 
 
Figure 13: Flows in CE and HPLC. 
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1.2.2.2 Sample stacking 
One of the simplest methods for sample pre-concentration is to induce stacking of the 
sample components this is easily accomplished by exploiting the ionic strength 
differences between the sample matrix and separation buffer. When the sample 
matrix is of lower ionic strength than the separation buffer (ten folds has been 
recommended), the sample components stack at the interface between the sample 
plug and the separation buffer (Figure 14). This results from the fact, that sample ions 
have an enhanced electrophoretic mobility in a lower conductivity environment. When 
a voltage is applied to the system, sample ions in the sample plug instantaneously 
accelerate towards the adjacent separation buffer zone where, on crossing the 
boundary, the higher conductivity environment induces a decrease in electrophoretic 
velocity and subsequent stacking of the sample components into a smaller buffer 
zone than the original sample plug. Within a short time, the ionic strength gradient 
dissipates and the charged analyte molecules begin to move from the stacking 
sample zone towards cathode. 
1.2.2.3 Electrode polarity 
Establishing the electrode polarity is important in capillary zone electrophoresis and 
is the default initial setting to be noted before the beginning of analysis. The normal 
polarity for CE is to have the anode (+) at the inlet and cathode (-) at the outlet. In this 
format, EOF is towards the cathode (detector/outlet). This is the standard polarity for 
most modes of CE. If set in the reversed polarity (cathode at inlet; anode at outlet), 
the direction of EOF is away from detector and only negatively charged analytes with 
electrophoretic mobility greater than the EOF will pass the detector [35]. 
1.2.2.4 Applied voltage 
Usually a voltage between 10 to 30 kV is used. Increasing the voltage will increase 
the sample migration and electro-osmotic flow, as well as shorten analysis time. It 
may also increase the sharpness of the peaks and improve resolution [35]. However, 
the advantages associated with increasing the voltage may be lost if the sample 
matrix ionic strength is much greater than the running buffer ionic strength and/or the 
increased production of Joule heat cannot be efficiently dissipated.  
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Figure 14: The sample stacking mechanism. 
1.2.2.5 Temperature effect 
Joule heating of the capillary results in a decrease of solution viscosity. This leads to 
a further increase in EOF, ion mobility, and analyte diffusion, which may ultimately 
result in band broadening. Joule heating is a consequence of the resistance of buffer 
to the current. Separation should be done with thermostatted capillary at close to 
ambient temperature. Whenever temperature control starts to be a problem, the 
usual strategy is to use a smaller bore capillary (less current reduces the heat 
production) or longer capillary (more surface area dissipates the heat generated). 
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1.2.2.6 Effect of capillary dimensions on separation 
1.2.2.6.1 Internal diameter 
Increasing the capillary internal diameter improves detection sensitivity (path length 
will be longer). However, this leads to less efficient dissipation of heat which then 
results in a temperature gradient across the capillary and band broadening due to 
thermal effects.  
1.2.2.6.2 Length 
Increasing the capillary length will increase migration (analysis) time. The increased 
length has no significant effect on separation in most cases. Exceptions are in chiral 
separation using CDs and in MEKC. In these cases the CDs and/or the micelles act 
as a pseudo-stationary phases and thus longer capillary allows more interaction. 
Also, as the length increases, there will be a concomitant decrease in the electrical 
field strength at constant voltage and, hence, higher voltage could be applied.  
1.2.2.7 Effect of pH 
Increasing the separation buffer pH will result in an increase in EOF. The buffer pH 
may be altered by other parameters such as temperature, ion depletion of the buffer 
(caused by repetitive use of the same separation buffer) and organic additives. A 
wide variety of buffers can be employed in CZE. Phosphate buffers are used around 
pH 2.5 and pH 7.0, and borate around pH 9 with a typical buffer concentration is 
50 - 100 mM.  
1.2.2.8 Ionic strength 
The choice of the buffer species can have a dramatic effect on separation by CE. 
Furthermore, increasing the ionic strength of the separation buffer has the effect of 
decreasing EOF and hence, increasing the separation time. Increasing the ionic 
strength will also increase the current at a constant voltage to the point where 
adequate thermostatting of the capillary becomes a concern. The advantage of 
having a high ionic strength, in addition to the obvious improvement in buffer 
capacity, is the reduction of analyte-wall interactions [36]. The net effect on the 
separation will be to improve resolution. It is provided that capillary thermostating 
capacity is not exceeded and the unwanted analyte degradation processes do not 
occur.  
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1.2.2.9 Buffer additives 
The addition of organic modifier to the separation buffer will have different effects, 
depending on the nature of the additive. One of the effects that often results is a 
change in EOF. For example, the addition of 1,4-diaminobutanes and diamino-
alkanes to the buffer has been proposed to enhance resolution by slowing EOF 
through a dynamic (non covalent) coating of the capillary wall, thus improving the 
resolution of proteins [37]. Other additives have the effect of decreasing both the 
conductivity of the buffer and EOF. In such cases the subsequent enhancement in 
resolution may be a combination of the slower EOF (i.e. increased migration time), 
decreased thermal diffusion, and improved analyte solubility. Methanol in buffer can 
increase the solubility and resolution of the analytes [38].  
1.2.3 Enantiomeric separation using capillary zone electrophoresis 
1.2.3.1 Introduction to enantiomeric drugs  
Many drugs in use (about 40%) are known to be chiral. It is well established that the 
pharmacological activity is often restricted to one of the enantiomers. In several 
cases unwanted side effects or even toxic effects can occur with the second 
enantiomer. Even if the side effects are not that drastic, the inactive enantiomer has 
to be metabolized and represents an unnecessary burden for the organism. The 
administration of the pure pharmacologically active enantiomer is therefore of great 
importance. The development of enantiomer separation methods for controlling 
synthesis, for enantiomeric purity check, and for pharmacodynamic studies is 
attracting increasing interest. Recently, pharmaceutical companies try to carry out 
stero-selective reactions in order to produce the pure wanted enantiomer. However 
these stero-selective reactions do produce some enantiomeric impurities. The 
importance of stereochemistry, and also the need for enantioselective analysis 
methods, has become well recognized [39].  Enantiomers are stereoisomers that 
display chirality that is having one or more asymmetric carbon centers, allowing them 
to exist as non-super-imposable mirror images of one another. These isomers are 
difficult to analyze as they are both physically and chemically identical in an achiral 
environment and differ only in the way they bend plane-polarized light and in their 
behaviour in a chiral environment. The first step toward separating enantiomers is to 
create diastereomers. Diastereomers may be created through chemical derivatization 
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with a "chiral" reagent, or they may be formed transiently through interactions with 
chiral selectors. The latter is usually the most desirable as it is the easiest to employ. 
1.2.3.2 Methods for separation of enantiomeric drugs  
Different chromatographic separation techniques have been reported for chiral 
separation. Those include high-performance liquid chromatography (HPLC) both 
reversed phase [40-46], and normal phase chromatography [47-51], supercritical-fluid 
chromatography (SFC) [52, 53], and capillary electrophoresis (CE) [54-63]. In HPLC 
a special chiral bounded stationary phase column mainly of cyclodextrin is used. SFC 
uses an eluent of carbon dioxide and a high viscous chiral based liquid stationary 
phase.  During recent years, it has been shown that capillary electrophoresis (CE) is 
an excellent technique for chiral separation.  
The main advantages of this technique are the high efficiency, the fast equilibrium 
time and the possibility of using new selectors, since only small amounts are 
required. Determination of enantiomeric excess is of special importance in a number 
of situations. Example is to evaluate the purity of chiral synthetic building blocks and 
chiral pharmaceuticals. Such impurities originate from the synthesis or may be a 
consequence of poor configurational stability. In many cases, determination of 
unwanted enantiomer impurity (distomer) in the presence of the active enantiomer 
drug (eutomer) is needed. According to the ICH guideline detection limits of 0.1% 
impurities relative to the main compound are widely accepted as a minimum 
requirement for chiral trace impurity determination.  
Chiral separations are among the most widely used applications of CE. Indirect 
methods are based on the formation of stable diastereoisomers with a chiral 
derivatization reagent. These diastereoisomers can then be separated, based upon 
their different physicochemical properties, using an achiral BGE. However, there are 
several drawbacks to this method. A suitable, nearly 100% pure enantiomeric 
derivatization reagent is needed [64], the derivatization procedure is time-consuming 
and reacting groups (amino, carboxyl) are requested [65]. Furthermore, racemization 
can take place during the derivatization process. The most widely used method is the 
direct chiral determination using chiral selectors added directly to the BGE. Chiral 
selectors include bile salts and some antibiotics as streptomycin but the most widely 
used ones are cyclodextrins [66-68].  
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1.2.3.3 Cyclodextrins as chiral selectors 
The use of CDs in CZE mode is by far the most popular means of obtaining chiral 
separation in CE. Cyclodextrins are natural and neutral occurring cyclic 
oligosaccharides composed of several glucopyranose units. They have a bucket-like 
shape with a cavity of different dimensions depending on the cyclodextrin type (the 
number of glucose units and the substituent groups). Their cavity is relatively 
hydrophobic and able to accept guest compounds of different types, particularly 
those with non-polar groups. The outside rim of the cyclodextrin is relatively 
hydrophilic due to the presence of hydroxyl groups (primary and secondary). 
Figure 15 gives the structure of native cyclodextrins. Analyte molecules can become 
included into the core of the cyclodextrin through their complexation. The hydroxyl 
groups in the rim of the cyclodextrin can enantioselectively interact with a chiral 
analyte during its migration along the capillary. The two types of interaction between 
enantiomer and cyclodextrin are presented schematically in Figure 16 [69].   
Drug enantiomers can fit inside the cavity of CD and have different interactions and 
individual binding constants. Thus, it is possible to chirally resolve them using 
cyclodextrin added into the CE electrolyte. There is a range of a native and 
derivatized cyclodextrins commercially available. The native CDs, α, β, and γ 
possess six, seven and eight glucose subunits, respectively. From theoretical point of 
view, the α -CD is best selected when the analyte does not contain an aromatic ring 
or contains one ring without ortho or meta substitution. The β-CD is best selected 
when the analyte contains one aromatic ring with ortho or meta substitution or two 
aromatic rings. The γ-CD is best selected when the analyte contains more than two 
aromatic rings [33]. However, in practice these rules may not apply as other factors 
and the selected separation conditions also control the success of separation. The 
surface hydroxyl group of the native cyclodextrin can be chemically replaced with 
various groups giving different types of derivatized uncharged and charged 
cyclodextrins (Table 4).   
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Figure 15: Structure of the native cyclodextrins. 
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Figure 16: Proposed mechanism of interaction between DNS-Phenylalanine and 
HS-γ-CD. A key interaction point for chiral recognition appears to be at the C3 
secondary hydroxyl. 
 
 
Table 4: Native and derivatized cyclodextrins. 
 
 
Cyclodextrin  Type  
α-Cyclodextrin Native cyclodextrin 
β-Cyclodextrin  Native cyclodextrin 
γ-Cyclodextrin Native cyclodextrin 
Hydroxypropyl-α-cyclodextrin  Derivatized uncharged cyclodextrin 
Hydroxypropyl-β-cyclodextrin Derivatized uncharged cyclodextrin 
Hydroxypropyl-γ-cyclodextrin Derivatized uncharged cyclodextrin 
Highsulfated-α-cyclodextrin Derivatized negatively charged cyclodextrin 
Highsulfated-β-cyclodextrin Derivatized negatively charged cyclodextrin 
Highsulfated-γ-cyclodextrin Derivatized negatively charged cyclodextrin 
Phosphated-α-cyclodextrin Derivatized negatively charged cyclodextrin 
Phosphated-β-cyclodextrin Derivatized negatively charged cyclodextrin 
Phosphated-γ-cyclodextrin Derivatized negatively charged cyclodextrin 
Succinylated-β-cyclodextrin  Derivatized negatively charged cyclodextrin 
Quaternary ammonium cyclodextrin Derivatized positively charged cyclodextrin 
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These derivatized CDs have different enantioselectivities than the native CDs and 
are generally more water soluble than the naturally occurring ones. 
Charged CDs offer the possibility of separating neutral drug enantiomers or 
enhancing the separation of ionic drugs. Figure 17 shows the structure of a 
cyclodextrin that has been chemically substituted with sulphate groups. These 
sulphated cyclodextrins have additional interactions with the analytes and therefore 
offer different separation possibilities. 
 
 
 
 
Figure 17: Chemical structure of highly sulphated β-cyclodextrin, R = (-SO3
-) or 
(-H). 
1.2.3.4 Advantages of CE over HPLC in chiral separation  
In CE different separation modes as CZE and MEKC can be used and there is no 
need for expensive special accessories as the chiral HPLC column because the 
chiral selector is simply added to the background electrolyte (BGE). Moreover 
different new chiral selectors could be tried or a combination of two in a dual system. 
Also smaller volumes of buffer and sample are used.  The reproducibility should in 
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principle be better than in HPLC as the chiral selector is replenished after each run. 
In addition higher efficiency and resolution can be obtained using CE for chiral 
separation. However, because of the low injection volume, the concentration 
sensitivity is low and stacking procedures are therefore sometimes needed. In 
addition, precision of injection is worse compared to HPLC. In the latter a known 
amount of sample is injected on column, which is not the case for CE due to the 
different injection mechanisms. 
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2. Materials and Methods  
2.1 Experimental HPLC part 
2.1.1 Chemicals and reagents 
Acetonitrile HPLC grade, pilocarpine hydrochloride 99% and propranolol 
hydrochloride 99% were purchased from Acros Organics (Belgium). Methanol HPLC 
grade was purchased from Fisher Scientific (United Kingdom). Phosphoric acid 85%, 
triethylamine, sulfuric acid, sodium lauryl sulphate, ammonia, lactose monohydrate, 
polyvidone 25000, microcrystalline cellulose and magnesium stearate were 
purchased from Merck (Germany). Human insulin synthetic 95-98% (HPLC) approx. 
24 IU/mg and tetrabutylammonium dihydrogen phosphat were purchased from 
Sigma-Aldrich (Switzerland). The following substances 1-[[4-[2-[(5- chloro-2-methoxy-
benzoyl) amino]ethyl]phenyl] sulphonyl]-3-cyclohexylurea (glibenclamide) (purity 
>99.9%), 5-chloro-2-methoxy-N-[2-(4-sulfamoyl-phenyl)ethyl]benzamide (related 
compound A) (99.0%), methyl[[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]-
sulfonyl]carbamate] (related compound B) (95.6%), 1-[[4-[2-[(3-ethyl-4-methyl-2-oxo-
2,5dihydro-1H-pyrrol-1-yl)carbonyl]-amino]ethyl]phenyl]sulphonyl]-3-(trans-4methyl-
cyclohexyl) urea (glimepiride) (99.7%) and Insuman® Basal 100 IU/ml suspension for 
injection were provided by Aventis (Germany). Anhydrous sodium sulphate was 
purchased from Lenziug (Australia). Potassium dihydrogen phosphate, sodium 
dihydrogen phosphate dihydrate, disodium hydrogen phosphate, and phosphoric acid 
85% were purchased from Riedel-de-Haën (Germany). Sodium starch glycolate and 
ferric oxide were purchased from Caelo (Germany), respectively. Nicotinic acid,  
resorcin, phenol,  salicylic acid, benzoic acid, 4-hydroxy benzoic acid and 2-naphthol, 
aniline, N-methylaniline, N-ethylaniline, 4-ethylaniline, dimethyaniline, N,N-
diethyaniline, codeine phosphate, ephedrine hydrochloride, theophiline 
ethyendiamine, atropine sulfate, yohimbine hydrochloride, papaverine hydrochloride 
and butylscopolamine bromide (all were gifts from different pharmaceutical 
companies). Bi-distilled water was used throughout. All used chemicals were at least 
of analytical grade. 
2.1.2 Instrumentation 
Analyses were performed on a Merck Hitachi HPLC system, consisting of a solvent 
pump (model L 6200 A), an autosampler (AS 2000A), a UV-VIS detector (L-4250), a 
diode array detector (L-7450), and an interface (D-6000). The column oven (T1) was 
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from Techlab (Erkerode, Germany). The data were collected and analyzed using the 
D7000 HSM software (Merck). The separation was performed on a Superspher 100 
RP-18e column (endcapped, 4 µm particle size, 125 mm × 4 mm, Merck) and a set of 
seven Chromolith Performance RP-18e (100 ×  4.6 mm, Merck). 
2.1.3 Separation conditions 
2.1.3.1 Pilocarpine 
2.1.3.1.1 Chromatographic conditions 
The mobile phase was prepared according to a previously recommended method 
[70] by mixing 980 ml buffer solution with 20 ml methanol (The buffer was prepared 
by mixing 13.5 ml of 85% phosphoric acid, 3 ml of triethylamine and water to a total 
volume of 1000 ml. The pH was adjusted to 3 by the addition of 50% sodium 
hydroxide). The mobile phase was degassed by sonication before use. The flow rate 
was 1ml/min on the conventional column, while different flow rates from 1 to 9 ml/min 
were applied on monolithic columns. The injection volume was 20 µl and the 
detection wavelength was 214 nm. All separations were performed at ambient 
temperature. 
2.1.3.1.2 Preparation of standard 
The buffer described in section 2.1.3.1.1 was used as sample diluent. Dilutions were 
carried out using the sample diluent, to obtain solutions of known concentrations to 
be used for the standard preparation and the assay purposes. The concentration 
levels described in European Pharmacopoeia 2005 (0.008-0.5 mg/ml) were used. 
2.1.3.1.3 Preparation of degradation products 
Solution a (Isopilocarpine): Isopilocarpine was obtained from pilocarpine. 1 ml of 
0.1 M sodium hydroxide solution was added to a 5 ml solution of 0.5 mg/ml 
pilocarpine hydrochloride in a 25 ml volumetric flask to allow deprotonation followed 
by the addition of 1 ml 0.1 M HCl to allow reprotonation. The volume of the finally 
resulting solution was completed to 25 ml by sample diluents. 
Solution b (Pilocarpic acid & isopilocarpic acid): Pilocarpic acid and isopilocarpic 
acid which are not commercially available were generated by base catalyzed 
hydrolysis in a way similar to [71]. To 5 ml of 1 mg/ml pilocarpine aqueous solution in 
a 25 ml volumetric flask, 100 µl of concentrated ammonia was added and the mixture 
was heated in an oven to 90 ºC for about 2 hours. The mixture was allowed to cool to 
room temperature and then diluted to 25 ml with sample diluent. 
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Pilocarpine/degradation products mixture: The final mixture that contains pilocarpine 
with its three degradation products was prepared by mixing 8 ml of solution a, 8 ml of 
solution b and 5 ml of 0.5 mg/ml pilocarpine hydrochloride solution. The solution was 
completed to a total volume of 25 ml using sample diluent. 
2.1.3.1.4 Addition of excipient 
Excipient for pilocarpine hydrochloride ophthalmic solution was prepared containing 
the inactive ingredients disodium edetate 4 mg, polyvinylpyrrolidone 1.7 mg, sodium 
dihydrogen phosphate 0.8 mg, disodium hydrogen phosphate 0.94 mg, sodium 
chloride 0.9 mg and benzalkonium chloride 0.13 mg in 100 ml of bi-distilled water. 
2.1.3.2 Propranolol 
2.1.3.2.1 Chromatographic conditions 
The mobile phase was prepared according to the method described in the European 
Pharmacopoeia 1997, by mixing 1.15 g sodium lauryl sulphate, 10 ml of a mixture of 
1 volume of sulfuric acid and 9 volumes of water, 20 ml of 17 g/l solution of 
tetrabutylammonium dihydrogen phosphate, 370 ml of water and 600 ml of 
acetonitrile. The pH of the finally resulting solution was corrected to 3.3 using diluted 
sodium hydroxide solution. The flow rate was 1 ml/min on the conventional column, 
while different flow rates (1 to 9 ml/min) were applied on monolithic column. The 
injection volume was 20 µl and the detection wavelength was 292 nm. All separations 
were performed at ambient temperature. 
2.1.3.2.2 Preparation of standard  
The primary stock solution of propranolol hydrochloride was prepared in the mobile 
phase to obtain solutions of known concentrations to be used for the standard 
preparation and the assay purposes in the range of 0.002 - 1 mg/ml. 
2.1.3.2.3 Preparation of degradation products  
The two main degradation products of propranolol hydrochloride are 3-(Naphthalene-
1-yloxy)propane-1,2-diol and 1,1'-[(1-Methylethyl)imino]bis[3-(naphthaline-1-yloxy)-
pro- pane-2-ol]. They were generated by basic hydrolysis by the addition of a 1 ml of 
0.1 M NaOH to a 5 ml solution of 1 mg/ml propranolol hydrochloride in a 25 ml 
volumetric flask. The solution was left for 20 min to allow hydrolysis. Then 1 ml 0.1 M 
hydrochloric acid was added to neutralize the solution. The volume of the finally 
resulting solution was completed to 25 ml with mobile phase. 
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2.1.3.2.4 Addition of excipient  
Excipient for propranolol hydrochloride tablets was prepared containing the following 
substances specified as a percentage of tablet weight, propranolol hydrochloride 
26.7% w/w, lactose monohydrate 51.3% w/w, microcrystalline cellulose 20% w/w, 
and magnesium stearate 2% w/w [72]. 
2.1.3.3 Glibenclamide and glimepiride 
2.1.3.3.1 Chromatographic conditions  
The mobile phase was prepared by dissolving 650 mg sodium dihydrogen phosphate 
dihydrate in 550 g water and adding two drops of phosphoric acid 85% and 351.5 g 
acetonitrile to 1000 ml. The pH of the resulting solution before the addition of 
acetonitrile was in the range of 3.0 - 3.3. The flow rate was 1.25 ml/min on the 
conventional column, while different flow rates (1.25 to 9 ml/min) were applied on 
monolithic columns. The injection volume was 10 µl and the detection wavelength for 
glibenclamide, related compounds A and B was 210 nm and for glimepiride was 228 
nm. The column oven temperature was set at 35˚C for all runs. 
2.1.3.3.2 Preparation of sample solvent 
The sample solvent consisted of 20 volumes of 4 mM phosphate buffer (pH 7) and 80 
volumes acetonitrile. The buffer was prepared based on British Pharmacopoeia 1999 
[73] by mixing 21.2 mg potassium dihydrogen phosphate and 34.65 mg sodium 
dihydrogen phosphate dihydrate in 100 ml water. 
2.1.3.3.3 Preparation of standard  
A synthetic mixture of drug product compounds was prepared containing 
glibenclamide, glimepiride and the related products A and B at different 
concentrations in the range of 0.001 - 0.240 mg/ml. 
2.1.3.3.4 Addition of excipient  
Inactive ingredients for glibenclamide and glimepiride tablets were prepared 
containing the following substances: 74.6 mg lactose monohydrate, 4.0 mg sodium 
starch glycolate, 0.5 mg polyvidone 25000, 10.0 mg microcrystalline cellulose, 0.5 mg 
magnesium stearate and 0.4 mg ferric oxide.  The mixture was homogenized by 
trituration in a mortar. 
 
 
 
2 Materials and Methods 
 
 41 
2.1.3.4 Insulin 
2.1.3.4.1 Chromatographic conditions 
The mobile phase was prepared by dissolving 28.4 g anhydrous sodium sulphate in 
1000 ml water followed by the addition of 2.7 ml of concentrated phosphoric acid 
85% (buffer pH 2.3). For the conventional column 74 volumes of the buffer were 
mixed with 26 volumes of acetonitrile. For monolithic columns, 74.5 volumes of the 
buffer were mixed with 25.5 volumes of acetonitrile. The mobile phase was degassed 
by sonication before use. The flow rate was 1 ml/min on the conventional column, 
while different flow rates from 1 to 9 ml/min were applied on monolithic columns. The 
injection volume was 10 µl and the detection wavelength was 214 nm. All separations 
were performed at ambient temperature. 
2.1.3.4.2 Preparation of standard 
Standard solutions of human insulin were prepared in 0.9% w/v sodium chloride 
solution with the addition of 5 drops of 0.1 M hydrochloric acid to improve solubility. 
Solutions of known concentrations to be used for the standard preparation and the 
assay purposes were prepared in the range of 0.03 to 3.00 mg/ml. 
2.1.3.4.3 Preparation of mixture  
Pharmaceutical preparation that contains human insulin commercially referred to as 
Insuman BasalTM 100 IU/ml (suspension for injection) was used. The other 
ingredients of Insuman BasalTM are: protamine sulphate, m-cresol, phenol, zinc 
chloride, sodium dihydrogen phosphate dihydrate, glycerol, sodium hydroxide and 
hydrochloric acid. 
2.1.3.5 Acid mixture 
2.1.3.5.1 Chromatographic conditions 
The used column was Chromolith Performance RP-18e (100 × 4.6 mm, Merck). The 
different pH buffers used during the method development were prepared according to 
Table 5. A mixture of methanol: 25 mM phosphate buffer pH 3 (10:90) was finally 
selected during method development as mobile phase. The flow program mentioned 
in Table 23 section 3.1.3.1.1 was finally selected. Detection wavelength was 273 nm.  
2.1.3.5.2 Preparation of standard 
A mixture of seven acidic compounds namely: nicotinic acid,  resorcin, phenol,  
salicylic acid, benzoic acid, 4-hydroxy-benzoic acid and 2-naphthol, has been created 
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by weighing 2 mg of each compound in a 10 ml volumetric flask and filling with water 
to the mark.   
2.1.3.6 Aniline and its derivatives mixture 
2.1.3.6.1 Chromatographic conditions 
The used column was Chromolith Performance RP-18e (100 × 4.6 mm, Merck).  
A mixture of phosphate buffer pH 5, 25 mM: methanol (55:45) was finally selected 
during method development as mobile phase. The flow program mentioned in Table 
24 section 3.1.3.1.2 was finally selected. All compounds were detected at 214 nm. 
2.1.3.6.2 Preparation of standard mixture 
A mixture of six basic compounds consisting of aniline and five derivatives, namely: 
N-methylaniline, N-ethylaniline, 4-ethylaniline, dimethylaniline and N,N-diethylaniline, 
has been created by weighing 2 mg of each compound in a 10 ml volumetric flask 
and filling to the mark with the mobile phase which was a mixture of phosphate buffer 
pH 5, 25 mM:methanol (55:45).   
 
Table 5: Buffer preparations.  
Standard 
solutions used for 
the preparation of 
2 l buffer solution 
pH 2 pH 3 pH 4 pH 5 pH 6 pH 7 pH 7.4 pH 8 
0.1M Phosphoric 
acid 6.86 ml/l 
282.5 55.0 - - - - - - 
0.1M Acetic acid 
5.8 ml/l 
- - 410.0 148.0 - - - - 
0.1M Sodium 
acetate solution  
8.2 g/l 
- - 90.0 352.0 - - - - 
0.1M Sodium 
dihydrogen-
phosphate 
dihydrate solution 
15.6 g/l 
217.5 445.0 - - 438.5 195.0 95.0 26.5 
0.1M Disodium 
hydrogenphosphate 
dihydrate solution 
17.8g/l 
- - - - 61.5 305.0 405.0 473.5 
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2.1.3.7 Alkaloid mixture 
2.1.3.7.1 Chromatographic conditions 
The used column was Chromolith Performance RP-18e (100 × 4.6 mm, Merck). 
A mixture of phosphate buffer 25 mM, pH 3: methanol (80:20) was finally selected 
during method development as mobile phase. The flow program mentioned in Table 
25 section 3.1.3.1.3 was finally selected. All compounds were detected at 214 nm. 
2.1.3.7.2 Preparation of standard mixture 
A basic mixture of seven alkaloids has been created by putting 2 mg of each in a 10 
ml volumetric flask and filling to the mark with the mobile phase which was a mixture 
of phosphate buffer 25 mM, pH 3: methanol (80:20).  The compounds were namely: 
codeine phosphate, ephedrine hydrochloride, theophiline ethylendiamine, atropine 
sulfate, yohimbine hydrochloride, papaverine hydrochloride and butylscopolamine 
bromide with two of its impurities butylscopolamine impurity a and butylscopolamine 
impurity b. 
2.2 Experimental CE 
2.2.1 Chemicals and reagent 
The following racemic drugs were analysed: atenolol hydrochloride, alprenolol 
hydrochloride, ephedrine hydrochloride, methadone hydrochloride, pindolol 
hydrochloride, promethazine hydrochloride, propranolol hydrochloride, tryptophan 
and verapamil hydrochloride (all gifts from different pharmaceutical companies). 
The cyclodextrin selectors used: α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, 
hydroxypropyl-α-cyclodextrin, hydroxypropyl-β-cyclodextrin, hydroxypropyl-γ- 
cyclodextrin, carboxymethyl-β-cyclodextrin and high sulphated-β-cyclodextrin were all 
purchased from Sigma-Aldrich (Germany). Succinyl-β-cyclodextrin was purchased 
from Sigma-Aldrich (Hungary). The α-cyclodextrin phosphate sodium salt and γ-
cyclodextrin phosphate sodium salt were purchased from Sigma-Aldrich 
(Switzerland). High sulfated-α-cyclodextrin and high sulfated-γ-CD was comer-
cialized as 20% (w/v) aqueous solutions from Beckman-Coulter (Fullerton, CA).  
2.2.2 Instrumentation  
Screening of racemic drugs were carried out on a UniCAM Crystal 310 CE System 
(UniCAM Ltd., Cambridge, United Kingdom) equipped with a Spectra Physics 100 UV 
detector. Bare fused silica capillaries were obtained from (Polymicro Technologies,  
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Phoenix, AZ, United State of America); 50 µm (i.d.), 62 cm total length (Lt), 
Ld = 48 cm to the detector window. A second instrument with different instrumental 
parameters was also used: A PrinCE 550 CE System (Prince Technologies, Emmen, 
Netherlands) equipped with a Lambda 1010 UV detector (Bischoff, Leonberg, 
Germany) and the bare fused silica capillary with a total length (Lt) amounted to 85 
cm, the length to the detection window (Ld) amounted to  = 31 cm. 
pH measurements were performed on a Metrohm 620 pH meter (Herisau, 
Switzerland). Rotilabo® - syringe filters were obtained from Carl Roth (PVDF, 0.22 
µm, Karlsruhe, Germany).  
2.2.3 Separation conditions  
2.2.3.1 Preparation of racemic solutions 
Racemic drugs were dissolved in the 5 mM phosphate buffer pH 2.5 (10 folds dilution 
of the running buffer) at a concentration of 0.2 mg/mL. All sample solutions were 
filtered through the 0.22 µm Rotilabo® - syringe filters obtained from Carl Roth (PVDF, 
Karlsruhe, Germany).  
2.2.3.2 Preparation of separation buffer 
A 50 mM phosphate buffer, pH 2.5 was prepared by dissolving 6.89 g sodium 
dihydrogen phosphate dihydrate in 1000 ml volumetric flask with bi-distilled water and 
adjusting the pH to 2.5 using 0.1 M perchloric acid.  
2.2.3.3 Cyclodextrin preparation 
Each of the cyclodextrin 2% solutions was prepared in the 50 mM phosphate buffer 
pH 2.5 by dissolving 40 mg CD in 2 ml of the phosphate buffer pH 2.5. For HS-α-CD 
and HS-γ-CD which were commercialized as 20% (w/v) aqueous solutions, the 2% 
solution was prepared by mixing 200 µl of the 20% solution with 1800 µl phosphate 
buffer pH 2.5. 
2.2.3.4 Electrophoretic conditions 
Pressure injections (50 mbar for 0.3 min) of standard sample solutions (racemic drug) 
were used. Complete filling technique of the capillary with cyclodextrin has been used. 
This technique involves filling the capillary and doing the run from a solution of CD in 
the 50 mM phosphate buffer pH 2.5 electrolytes. Partial filling technique, which 
involves filling the capillary from a solution of CD in the buffer, then doing the run from 
the buffer solution without CD was not successful (did not lead to any separation). The 
running buffer contained 2% of any of the CD. The voltages were either 25 kV or -25 
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kV depending on the separation mode (normal or reversed). For negatively charged 
cyclodextrins the reversed separation mode was found to be more effective for basic 
drug enantiomeric separation. Temperature of the capillary was set to 25°C. 
Detection was carried out at 200 nm for all compounds. The capillaries were 
conditioned before use by successive washings (under a pressure of 1500 
mbar) for 30 min with 0.1 M sodium hydroxide then 30 min water, followed by a 30 
min flush with run buffer. 
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3 Results  
3.1 Results HPLC part 
3.1.1 Transferred methods 
3.1.1.1 Optimization of chromatographic parameters  
In order to evaluate the performance of monolithic columns it was necessary to 
compare with that of particle packed columns. HPLC methods previously described 
for the determination of pilocarpine, propranolol, glibenclamide,  glimepiride and 
insulin using conventional particle-packed C18 columns have been adapted to our 
conventional column Superspher 100 RP-18e column (endcapped, 4 µm particle 
size, 125 mm × 4 mm, Merck). Structures of pilocarpine, propranolol, glibenclamide, 
insulin each with its related compounds are shown in Figures 18, 19, 20 and 21, 
respectively. The methods were then transferred without further modification to the 
monolithic Chromolith Performance RP-18e (100 × 4.6 mm, Merck). For pilocarpine a 
method described in [71] was taken. The used method has been previously tested on 
a set of conventional C18 columns, however was not tested on Superspher 
commercial type column, which was used in this study. For propranolol the method 
used based on European Pharmacopoeia 1997 [74], however some parameters were 
changed including the flow rate and the properties of the octadecylsilyl silica column 
used. The conventional Superspher 100 RP-18e column (endcapped, 4 µm particle 
size, 125 mm × 4 mm, Merck) was used with a flow rate of 1 ml/min, instead of a 5 
µm particle size, 200 mm × 5 mm octadecylsilyl silica column at a flow rate of 1.8 
ml/min as specified in European Pharmacopoeia 1997. The conventional C18 based 
method used for glibenclamide, glimepiride and the two related substances was 
formerly developed in our laboratories [75].  For insulin the method was adapted from 
the European Pharmacopoeia 2005 [76], isocratic elution with a 26% acetonitrile 
concentration was chosen and the Superspher 12.5 cm column packed with 4 µm 
particles instead of 25 cm column packed with 5 µm particles specified in the 
European Pharmacopoeia 5th edition. 
3.1.1.2 Method transfer and validation  
Methods for pilocarpine, propranolol, glibenclamide and glimepiride were found to be 
successfully transferable from the conventional particle-packed to the monolithic rod 
columns without any modification. For the relatively larger molecule insulin, the 
method was not successfully transferred from the first go.  
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Figure 18: Degradation scheme for pilocarpine. 
 
 
 
 
Figure 19: Structure of propranolol hydrochloride and its two degradation 
products. 
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Figure 20:  Structure of glibenclamide and its related substances. 
 
 
 
 
 
 
 
 
 
 
 
Figure 21:  Structure of human insulin. 
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 Glu-Val-Ile-Gly-H 
   4     3    2    1 
  
 Glu-Cys-Cys-Thr-Ser-Ile-Cys-Se-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn-OH 
   5     6     7      8     9   10  11   12  13   14   15   16    17   18    19   20    21 
 
Chain A 
Asn-Val-Phe-H                                HO-Thr-Lys-Pro-Thr-Tyr-Phe-Phe-Gly-Arg 
  3     2     1                                              30   29   28   27   26    25   24    23   22 
         
 
Gln-His Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu 
  4    5     6      7      8    9    10   11    12  13   14   15    16   17   18   19    20   21 
 
Chain B 
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The peak of insulin was eluted too early when the method was firstly transferred to 
the monolithic column, so it overlapped with the peak of m-cresol (Figure 22). 
However, by decreasing the amount of the organic modifier (acetonitrile) in the 
mobile phase from 26% to 25.5% a good resolution was obtained (results will be 
shown later in Figures 23-26). It has been demonstrated, that the same elution order 
and pattern of the used mixtures were obtained in monolithic and conventional 
columns. This indicates that the selectivity of the two column types is equivalent due 
to the very similar chemical properties of the two column types. 
3.1.1.2.1 Specificity  
The specificity of the methods was examined by observing if there was any 
interference of the inactive ingredients of the pharmaceutical preparations in each 
drug case. The HPLC chromatograms recorded for the inactive ingredients of the 
analyzed compounds showed no peaks at the retention times of the active drugs and 
their degradation products or related compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Representative chromatogram for phenol (1), m-cresol (2), human 
insulin (3) and 21-desamido human insulin (4) on monolithic (Chromolith 
Performance RP-18e) column at a flow rate of 1ml/min. Mobile phase consists 
of buffer pH = 2.3: acetonitrile (74:26, v/v). 
 
1 2 3
4
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The specificity was also demonstrated by the good separation of the degradation 
products and/or related compounds from the main compound peak in each method.  
3.1.1.2.2 Accuracy  
The accuracy of the methods was tested by determination of the recovery using the 
excipient used in drug formulation of each of the used drugs. Recovery values are 
shown in Table 6. Results indicate a good recovery for all of the tested compounds. 
 
Table 6: List of recovery results for pilocarpine, propranolol, glibenclamide and 
glimepiride at three concentration levels. 
 
 
Drug 
Column 
type 
Theoretical 
value 
(mg/ml) 
Mean 
recovery* 
(mg/ml) 
Recovery 
(%) 
RSD 
(%) 
0.008 0.0076 95.36  0.84  
0.200 0.1920 96.00  0.65  
Superspher 
RP-18e 
0.500 0.4960 99.20  0.70  
0.008 0.0077 96.50  0.81  
0.200 0.1960 98.23  0.66  
pilocarpine 
hydrochloride Chromolith 
Performance 
RP-18e 0.500 0.4990 99.80  0.30  
0.020 0.0197 98.95  1.97  
0.040 0.0395 98.00  1.26  
Superspher 
RP-18e 
0.080 0.0794 99.27  0.91 
0.020 0.0198 99.00  1.91  
0.040 0.0398 99.5 0 1.23  
propranolol 
hydrochloride Chromolith 
Performance 
RP-18e 0.080 0.0796 99.60  1.00  
0.160 0.1596 99.80 0.69  
0.200 0.2001 100.05  1.27 
Superspher 
RP-18e 
0.240 0.2393 99.71  0.91 
0.160 0.1598 99.92  0.56  
0.200 0.1996 99.83  0.70  
glibenclamide 
Chromolith 
Performance 
RP-18e 0.240 0.2402 100.08  0.69 
0.160 0.1612 100.75 0.86 
0.200 0.1976 98.80 0.91 
Superspher 
RP-18e 
0.240 0.2397 99.87 1.13 
0.160 0.1610 100.62 1.02 
0.200 0.1994 99.70 0.86 
glimepiride 
Chromolith 
Performance 
RP-18e 0.240 0.2405 100.20 0.95 
 
* Mean value of 10 determinations. 
 
3.1.1.2.3 Precision 
Precision which was an important topic of this study was carefully tested. To ensure 
assay precision within day (5 injections were performed each day) and between days 
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(determined at 5 days) precisions were assessed at 3 concentration levels on the 
conventional (Superspher) and the monolithic columns for each separation. Precision 
results for pilocarpine, propranolol, glibenclamide, and insulin are summarized in 
Tables 7-a and b, 8-a and b, 9-a and b and 10-a and b, respectively.  
 
Table 7-a: Within day repeatabilities of pilocarpine hydrochloride on 
conventional and monolithic columns over a concentration range 0.008 - 0.500 
mg/ml using n = 5.* 
 
 
Within day repeatability 
RSD % of AUC 
 
 
Within day 
repeatability 
RSD % of tR 
 
 
 
Column type and No. 
 0.008 
mg/ml 
0.200 
mg/ml 
0.500 
mg/ml 
 
(n = 15) 
 
Superspher 100 RP-18e column 
 
0.84 0.70 0.88 0.52 
1 ml/min 0.85  0.60 0.54 0.45 
Chromolith Performance  
RP-18e 
Batch No. Um 1042 
Rod No. 1042/020 
4 ml/min 0.70 0.52 0.40 0.66 
1 ml/min 0.50 0.77 0.44 0.44 
Chromolith Performance  
RP-18e 
Batch No. Um 1043 
Rod No. 1043/041 4 ml/min 0.69 0.49 0.68 0.49 
1 ml/min 0.68 0.51 0.34 0.42 
Chromolith Performance  
RP-18e 
Batch No. Um 1045 
Rod No. 1045/036 4 ml/min 0.74 0.77 0.87 0.45 
1 ml/min 0.61 0.73 0.75 0.52 
Chromolith Performance  
RP-18e 
Batch No. Um 1042 
Rod No. 1042/012 
4 ml/min 0.64 0.47 0.31 0.38 
1 ml/min 0.66 0.54 0.61 0.38 
Chromolith Performance 
 RP-18e 
Batch No. Um 1043 
Rod No. 1043/032 
4 ml/min 0.67 0.68 0.67 0.45 
1 ml/min 0.73 0.69 0.44 0.51 Chromolith Performance 
 RP-18e 
Batch No. Um 1045 
Rod No. 1045/023 
4ml/min 0.58 0.62 0.49 0.48 
 
* Results on monolithic columns include repeatabilities at flow rates of 1 and 4 ml/min 
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Table 7-b: Between days repeatabilities for pilocarpine hydrochloride on 
conventional and monolithic columns over a concentration range of 0.008 -
 0.500 mg/ml using n = 5. * 
 
 
 
Between day 
repeatability 
RSD % of AUC 
 
Between 
day 
repeatability 
RSD % of tR 
 
 
 
Column type and No. 
0.008 
mg/ml 
0.200 
mg/ml 
0.500 
mg/ml 
 
(n = 15) 
 
Superspher 100 RP-18e column 
 
1.16 0.90 0.84 0.66 
1 ml/min 0.87 0.67 0.84 0.65 
Chromolith 
Performance RP-18e 
Batch No. Um 1042 
Rod No. 1042/020 4 ml/min 0.85 0.76 0.87 0.65 
1 ml/min 0.51 0.72 0.40 0.53 
Chromolith 
Performance RP-18e 
Batch No. Um 1043 
Rod No. 1043/041 
4 ml/min 0.59 0.81 0.89 0.52 
1 ml/min 0.73 0.53 0.38 0.42 
Chromolith 
Performance RP-18e 
Batch No. Um 1045 
Rod No. 1045/036 
4 ml/min 0.88 0.43 0.85 0.54 
1 ml/min 0.53 0.54 0.79 0.51 Chromolith 
Performance RP-18e 
Batch No. Um 1042 
Rod No. 1042/012 
4 ml/min 0.62 0.74 0.70 0.51 
1 ml/min 0.69 0.78 0.87 0.58 
Chromolith         
Performance RP-18e 
Batch No. Um 1043 
Rod No. 1043/032 4 ml/min 0.57 0.66 0.71 0.53 
1 ml/min 0.73 0.58 0.53 0.68 
Chromolith 
Performance RP-18e 
Batch No. Um 1045 
Rod No. 1045/023 
4 ml/min 0.50 0.80 0.71 0.76 
 
 
 
* Results on monolithic columns include repeatabilities at flow rates of 1 and 4 ml/min 
 
 
 
 
3 Results 
 
 53 
Table 8-a: Within day repeatability for propranolol hydrochloride on 
conventional and monolithic columns over the concentration range 0.002 –
 1.000 mg/ml, using n = 5.* 
 
* 
Results on monolithic columns include repeatabilities at flow rates of 1 and 4 ml/min 
 
Table 8-b: Between days repeatabilities for propranolol hydrochloride on 
conventional and monolithic columns over the concentration range 0.002 – 1.00 
mg/ml, using n = 5.* 
*Results on monolithic columns include repeatabilities at flow rates of 1 and 4 ml/min. 
Within day 
repeatability 
RSD (%) of AUC 
Within day 
repeatability 
RSD (%) of tR 
 
 
 
Column type and No. 0.002 
mg/ml 
0.500 
mg/ml 
1.000 
mg/ml 
 
(n = 15) 
 
Superspher 100 RP-18e column 
 
1.27  0.70  0.69 0.76 
1 ml/min 0.78 0.66 0.43 0.42 Chromolith Performance 
RP-18e 
Batch No. Um 1042 
Rod No. 1042/020 
4 ml/min 0.92 0.61 0.57 0.66 
1 ml/min 0.88 0.86 0.61 0.56 
Chromolith Performance 
RP-18e 
Batch No. Um 1043 
Rod No. 1043/041 
4 ml/min 0.91 0.96 0.60 0.66 
1 ml/min 0.79 0.61 0.58 0.66 
Chromolith Performance 
RP-18e 
Batch No. Um 1045 
Rod No. 1045/036 4 ml/min 0.92 0.56 0.38 0.66 
Between day 
repeatability 
RSD (%) of AUC 
Between day 
repeatability 
RSD (%) of tR 
 
 
 
Column type and No. 0.002 
mg/ml 
0.500 
mg/ml 
1.00 
mg/ml 
 
(n = 15) 
 
Superspher 100 RP-18e column 
 
1.17 1.01 0.97 0.85 
1 ml/min 0.96 0.96 0.81 0.79 Chromolith Performance 
RP-18e 
Batch No. Um 1042 
Rod No. 1042/020 
4 ml/min 0.99 0.87 0.90 0.72 
1 ml/min 0.94 0.85 0.70 0.82 
Chromolith Performance 
RP-18e 
Batch No. Um 1043 
Rod No. 1043/041 
4 ml/min 0.95 1.00 0.89 0.52 
1 ml/min 0.89 0.96 0.74 0.90 
Chromolith Performance 
RP-18e 
Batch No. Um 1045 
Rod No. 1045/036 4 ml/min 0.96 0.68 0.71 0.71 
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Table 9-a: Within day repeatability for glibenclamide on conventional and  
monolithic columns over a concentration range 0.01 - 0.24 mg/ml using n = 5. * 
* Rresults on monolithic columns include repeatabilities at flow rates of 1.25 and 4 ml/min 
Table 9-b: Between days repeatability for glibenclamide on conventional and 
monolithic columns over a concentration range 0.01 - 0.24 mg/ml using n = 5.* 
 
* Results on monolithic columns include repeatabilities at flow rates of 1.25 and 4 ml/min 
 
Within day  
repeatability 
RSD (%) of AUC 
Within day 
repeatability 
RSD (%) of tR 
 
Column type and No. 
0.01 
mg/ml 
0.12 
mg/ml 
0.24 
mg/ml 
 
(n = 15) 
Superspher 100 RP-18e column 
Flow rate 1.25 ml/min 
0.99  0.62  0.64 0.16 
1.25 ml/min 0.79 0.65 0.36 0.10 
Chromolith Performance  
RP-18e 
Batch No. Um 1042 
Rod No. 1042/020 
4 ml/min 0.90 0.59 0.41 0.00 
1.25 ml/min 0.89 0.51 0.64 0.00 
Chromolith Performance  
RP-18e 
Batch No. Um 1043 
Rod No. 1043/041 4 ml/min 0.74 0.52 0.57 0.00 
1.25 ml/min 0.82 0.52 0.46 0.32 Chromolith Performance  
RP-18e 
Batch No. Um 1045 
Rod No. 1045/036 
4 ml/min 0.84 0.63 0.55 0.20 
Between day 
repeatability 
RSD (%) of AUC 
Between day 
repeatability 
RSD (%) of tR 
 
 
 
Column type and No. 0.01 
mg/ml 
0.12 
mg/ml 
0.24 
mg/ml 
 
(n = 15) 
Superspher 100 RP-18e column 
Flow rate 1.25 ml/min 
1.25 0.71 0.75 0.85 
1.25 ml/min 0.84 0.72 0.60 0.21 
Chromolith Performance  
RP-18e 
Batch No. Um 1042 
Rod No. 1042/020 
4ml/min 0.93 0.68 0.61 0.27 
1.25 ml/min 0.82 0.62 0.68 0.21 
Chromolith Performance  
RP-18e 
Batch No. Um 1043 
Rod No. 1043/041 4ml/min 0.89 0.69 0.74 0.54 
1.25 ml/min 0.92 0.57 0.53 0.39 Chromolith Performance  
RP-18e 
Batch No. Um 1045 
Rod No. 1045/036 
4 ml/min 0.92 0.67 0.61 0.27 
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Table 10-a: Within day repeatability for human insulin on conventional and 
monolithic columns over a concentration range 0.03 - 0.30 mg/ml using n = 5.* 
*Results on monolithic columns include repeatabilities at flow rates of 1 and 4 ml/min. 
Table 10-b: Between days repeatability human insulin on conventional and 
monolithic columns over a concentration range 0.03 -  0.30 mg/ml using n = 5.* 
*Results on monolithic columns include repeatabilities at flow rates of 1 and 4 ml/min 
 
 
Within day repeatability 
RSD (%) of AUC 
 
 
Within day 
repeatability 
RSD (%) of tR 
 
 
 
Column type and No. 
0.03 
mg/ml 
0.30 
mg/ml 
3.00 
mg/ml 
 
(n = 15) 
Superspher 100 RP-18e column 
 
1.08  0.68  0.74 0.67 
1 ml/min 0.84 0.61 0.73 0.54 Chromolith Performance 
 RP-18e 
Batch No. UM1042 
Rod No. 1042/020 
4 ml/min 0.96 0.78 0.50 0.58 
1 ml/min 0.89 0.42 0.31 0.57 
Chromolith Performance 
 RP-18e 
Batch No. UM1043 
Rod No. 1043/041 
4 ml/min 0.67 0.84 0.59 0.45 
1 ml/min 0.87 0.57 0.45 0.35 
Chromolith Performance  
RP-18e 
Batch No. UM5020 
Rod No. 5020/028 4 ml/min 0.75 0.55 0.62 0.43 
Between day  
repeatability 
RSD (%) of AUC 
Between day 
repeatability 
RSD (%) of tR 
 
 
 
Column type and No. 0.03 
mg/ml 
0.30 
mg/ml 
3.00 
mg/ml 
 
(n = 15) 
Superspher 100 RP-18e column 
 
1.20 0.96 0.90 0.98 
1 ml/min 0.79 0.95 0.70 0.75 
Chromolith Performance  
RP-18e 
Batch No. UM1042 
Rod No. 1042/020 4 ml/min 1.03 0.91 0.75 0.66 
1 ml/min 0.97 0.75 0.87 0.70 
Chromolith Performance 
 RP-18e 
Batch No. UM1043 
Rod No. 1043/041 
4 ml/min 0.93 0.73 0.93 0.80 
1 ml/min 0.97 0.93 0.50 0.82 
Chromolith Performance  
RP-18e 
Batch No. UM5020 
Rod No. 5020/028 
4 ml/min 0.97 0.85 0.90 0.60 
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Column to column reproducibility for Chromolith Performance was measured in each 
drug method. A set of six monolithic columns originating from three different batches 
were tested for the pilocarpine method. For the propranolol, glibenclamide and insulin 
methods, column to column reproducibility was tested using three monolithic columns 
from different batches. Results are summarized in Table 11. A total of seven 
monolithic columns from 4 different batches were used in this study. 
 
Table 11: Monolithic column to column reproducibility calculated for each 
method, 7 different columns from 4 different batches were used in this 
estimation.  
 
Drug method 
The used 
Chromolith 
Performance 
columns 
RSD (%) of AUC* RSD (%) of tR 
pilocarpine 
hydrochloride 
Rod No. 1042/020 
Rod No. 1042/012 
Rod No. 1043/032 
Rod No. 1043/041 
Rod No. 1045/036 
Rod No. 1045/023 
0.30 to 0.94 0.68 
propranolol 
hydrochloride 
Rod No. 1042/020 
Rod No. 1043/041 
Rod No. 1045/036 
0.36 to 1.25 0.66 
glibenclamide 
and glimepiride 
Rod No. 1042/020 
Rod No. 1043/041 
Rod No. 1045/036 
0.33 to 1.09 0.63 
insulin 
Rod No. 1042/020 
Rod No. 1043/041 
Rod No. 5020/028 
0.10 to 0.70 0.60 
 
* RSD% range is due to determination at different concentration levels. 
 
3.1.1.2.4 Linearity 
The calibration curves (peak area vs. concentration) for the used drugs were 
investigated over a wide concentration range. Residual plot did not show any trend. 
Results were found to be linear with high correlation coefficients (Table 12). 
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Table 12: Linearity of the 5 analyzed compounds.  
 
Compound Column type 
Concentration 
range (mg/ml) 
R2 
Chromolith Performance 
RP-18e 
0.008 - 0.500 0.9996 pilocarpine 
hydrochloride 
Superspher 100 RP-18e  0.008 - 0.500 0.9998 
Chromolith Performance 
RP-18e 
0.002 - 1.000 0.9988 propranolol 
hydrochloride 
Superspher 100 RP-18e 0.002 - 1.000 0.9992 
Chromolith Performance 
RP-18e 
0.010 - 0.240 0.9998 
glibenclamide 
Superspher 100 RP-18e 0.010 - 0.240 0.9996 
Chromolith Performance 
RP-18e 
0.010 - 0.240 0.9999 
glimepiride 
Superspher 100 RP-18e 0.010 - 0.240 0.9999 
Chromolith Performance 
RP-18e 
0.030 - 3.000 0.9998 
insulin 
Superspher 100 RP-18e 0.030 - 3.000 0.9998 
 
3.1.1.2.5 Detection and quantitation limits 
Limit of detection (LOD, S/N = 3) and an estimate for the limit of quantitation (LOQ, 
S/N = 10)  for all the tested drugs on monolithic columns at flow rates of 1 as well as 
4 ml/min were found to be lower on the monolithic than on the conventional column. 
Results of linearity, detection and quantitation limits are summarized in Table 13. 
 
Table 13: Detection and quantitation limits of the 5 analyzed compounds.  
 
Compound column type 
Detection 
limit(µg/ml) 
Quantitation 
limit (µg/ml) 
Chromolith Performance 
RP-18e 
0.1700 0.500 
pilocarpine 
Superspher 100 RP-18e  0.3100 1.000 
Chromolith Performance 
RP-18e 
0.0120 0.040 
propranolol 
Superspher 100 RP-18e 0.0610 0.200 
Chromolith Performance 
RP-18e 
0.1220 0.400 
glibenclamide 
Superspher 100 RP-18e 0.1240 0.410 
Chromolith Performance 
RP-18e 
0.1520 0.506 
glimepiride 
Superspher 100 RP-18e 0.1570 0.523 
Chromolith Performance 
RP-18e 
0.0008 0.002 
insulin 
Superspher 100 RP-18e 0.0013 0.004 
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3.1.1.3 Performance Parameter 
Peak performance parameters for pilocarpine, propranolol, glibenclamide and insulin 
were also calculated according to fundamental equations, results are shown in 
Tables 14, 15, 16, and 17, respectively. The least decrease in theoretical plate 
number (N) with increase in flow rate from 1 up to 9 ml/min was found in propranolol 
method, while the highest decrease was found in glibenclamide method. 
 
 
Table 14: Performance parameters for pilocarpine on conventional and 
monolithic columns*. 
 
 
 
 
Column type 
 
Theoretical plate N 
(Plate per column 
for pilocarpine) 
 
Asymmetry 
factor for 
pilocarpine 
Peak 
 
Resolution (Rs) 
pilocarpine/pilocarpic 
acid 
Conventional C18 
(flow rate 1 ml/min) 
1783 1.70 2.10 
Monolithic C18 
(flow rate 1 ml/min) 
3648 1.26 2.78 
Monolithic C18 
(flow rate 2 ml/min) 
3074 1.28 2.33 
Monolithic C18 
(flow rate 3 ml/min) 2559 1.23 2.23 
Monolithic C18 
(flow rate 4 ml/min) 
2488 1.22 2.13 
Monolithic C18 
(flow rate 5 ml/min) 
2415 1.21 1.92 
Monolithic C18 
(flow rate 6 ml/min) 
1950 1.35 1.80 
Monolithic C18 
(flow rate 7 ml/min) 
1777 1.40 1.58 
Monolithic C18 
(flow rate 8 ml/min) 
1430 1.32 1.43 
Monolithic C18 
(flow rate 9 ml/min) 
1336 1.30 1.32 
 
*The following equations were used to calculate the above mentioned chromatographic parameters: 
(N = 16 (tR/w)
2
, asymmetry factor (AF) = A/B at 10% of peak height (A & B are the two half widths of 
the peak center at each side at 10% height from the peak base) and resolution Rs = 2(tR2-tR1/w2+w1). 
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Table 15: Performance parameters for propranolol on conventional and 
monolithic columns*. 
 
 
 
*The following equations were used to calculate the above mentioned chromatographic parameters: 
(N = 16 (tR/w)
2
, asymmetry factor (AF) = A/B at 10% of peak height (A & B are the two half widths at 
each side of the peak center) and resolution Rs = 2(tR2-tR1/w2+w1)  
 
 
Compared to the traditional particulate column, monolithic columns were found to 
produce the same or better resolution and peak symmetry in a shorter run time 
(taking in account the small difference in column length) at the same flow rate of 1 
ml/min. With the application of higher flow rates on Chromolith Performance columns 
small reductions in resolution were observed. However at a flow rate of 4 ml/min the 
resolution obtained with the monolithic columns was still convenient (Rs ≥ 2) with the 
advantage of strongly reducing the total runs time. This reduces the time 
consumption for routine series of analyses.  Representative chromatograms for the 
four drug methods (pilocarpine, propranolol, glibenclamide-glimepiride and insulin) on 
 
 
Column type 
 
Theoretical plate N 
(Plate per column for 
propranolol 
hydrochloride) 
 
Asymmetry 
factor for 
propranolol 
Peak 
 
Resolution (Rs) 
propranolol impurity 
A/propranolol 
 
Conventional C18 
(flow rate 1 ml/min) 
379 1.4 4.39 
Monolithic C18 
(flow rate 1 ml/min) 
1120 1.1 4.40 
Monolithic C18 
(flow rate 2 ml/min) 
980 1.1 4.18 
Monolithic C18 
(flow rate 3 ml/min) 
925 1.1 3.26 
Monolithic C18 
(flow rate 4 ml/min) 
867 1.2 2.80 
Monolithic C18 
(flow rate 5 ml/min) 
858 1.1 2.00 
Monolithic C18 
(flow rate 6 ml/min) 
792 1.1 1.94 
Monolithic C18 
(flow rate 7 ml/min) 
769 1.1 1.80 
Monolithic C18 
(flow rate 8 ml/min) 
757 1.2 1.66 
Monolithic C18 
(flow rate 9 ml/min) 
694 1.1 1.58 
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conventional and monolithic columns are shown in Figures 23, 24, 25 and 26, 
respectively. The peak symmetry was better in case of monolithic columns compared 
to the conventional column. The height equivalent to theoretical plate was used to 
measure efficiency depending on flow rate. 
 
Table 16: Performance parameters for glibenclamide and the two related 
compounds on conventional and monolithic columns*. 
 
 
*The following equations were used to calculate the above mentioned chromatographic parameters: 
(N =16 (tR/w)
2
, asymmetry factor (AF) = A/B at 10% of peak height (A & B are the two half widths at 
each side of the peak center) and resolution Rs = 2(tR2-tR1/w2+w1). 
 
 
 
 
 
 
 
 
 
 
 
Column type 
 
 
Theoretical plate N 
(Plate per column 
for glibenclamide) 
 
Asymmetry 
factor for 
glibenclamide 
Peak 
 
Resolution (Rs) 
Compound a 
/compound b 
 
Conventional C18 
(flow rate 1,25 ml/min) 
4435 1.8 3.40 
Monolithic C18 
(flow rate 1,25 ml/min) 
7964 1.0 4.10 
Monolithic C18 
(flow rate 2ml/min) 
7540 1.1 3.86 
Monolithic C18 
(flow rate 3 ml/min) 
6725 1.1 3.20 
Monolithic C18 
(flow rate 4 ml/min) 
6151 1.0 2.80 
Monolithic C18 
(flow rate 5 ml/min) 
5807 1.0 2.40 
Monolithic C18 
(flow rate 6 ml/min) 
5003 1.1 1.90 
Monolithic C18 
(flow rate 7 ml/min) 
4328 1.0 1.70 
Monolithic C18 
(flow rate 8 ml/min) 
3755 1.0 1.40 
Monolithic C18 
(flow rate 9 ml/min) 
2822 1.1 1.13 
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Table 17: Performance parameters for human insulin on conventional and 
monolithic columns.* 
 
 
*The following equations were used to calculate the above mentioned 
chromatographic parameters: (N =16 (tR/w)
2, asymmetry factor (AF) = A/B at 10% of 
peak height (A & B are the two half widths at each side of the peak center) and 
resolution Rs = 2(tR2-tR1/w2+w1) 
 
Column efficiency was measured by plotting the height equivalent to theoretical 
plates which is abbreviated as (HETP) or simply referred to as plate height (H) 
against the flow rates of the mobile phase (Figure 27). The plate height H was 
calculated from the column length L and theoretical plate N according to H = L/N.  
 
 
Column type 
 
Theoretical 
plate N 
(Plate per 
column for 
human insulin) 
 
Asymmetry 
factor for 
human 
insulin Peak 
 
Resolution (Rs) 
human 
insulin/21-
desamido insulin 
 
Conventional C18 
(flow rate 1 ml/min) 
1665 1.2 2.60 
Monolithic C18 
(flow rate 1 ml/min) 
3003 1.2 4.50 
Monolithic C18 
(flow rate 2ml/min) 
2809 1.2 4.10 
Monolithic C18 
(flow rate 3 ml/min) 
2605 1.2 3.95 
Monolithic C18 
(flow rate 4 ml/min) 
2379 1.1 3.74 
Monolithic C18 
(flow rate 5 ml/min) 
2174 1.0 3.49 
Monolithic C18 
(flow rate 6 ml/min) 
2077 1.0 3.35 
Monolithic C18 
(flow rate 7 ml/min) 
1808 1.1 3.32 
Monolithic C18 
(flow rate 8 ml/min) 
1615 1.1 3.27 
Monolithic C18 
(flow rate 9 ml/min) 
1478 1.0 3.20 
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Figure 23: Representative chromatograms for pilocarpine hydrochloride and its 
degradation products on conventional (Superspher RP-18e) column, and on 
monolithic (Chromolith Performance RP-18e) column at different flow rates 
from 1 to 9 ml/min. Mobile phase consists of a buffer pH = 3: methanol (980:20, 
v/v). Difference in peak intensity between conventional and monolithic columns 
is due to difference in concentration of pilocarpine and its degradation 
products. 
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Figure 24: Representative chromatograms for propranolol hydrochloride (peak 
2) and its two Degradation products a & b (peaks 1 & 3, respectively) on 
conventional (Superspher RP-18e) and on Monolithic (Chromolith Performance 
RP-18e). Mobile phase consists of buffer pH = 3.3: acetonitrile (40:60, v/v). 
3 Results 
 
 64 
 
 
 
Figure 25: Representative chromatograms for related compound a (1) related 
compound b (2), glibenclamide (3) & glimepiride (4) on conventional 
(Superspher RP-18e) and on monolithic (Chromolith Performance RP-18e) 
columns at different flow rates from 1,25 to 9 ml/min. Mobile phase consist of 
buffer pH = 3:acetonitrile (55:45, v/v). 
3 Results 
 
 65 
 
 
 
Figure 26: Representative chromatograms for phenol (1), m-cresol (2), human 
insulin (3) & 21-desamido human insulin (4) on conventional (Superspher RP-
18e) and on monolithic (Chromolith Performance RP-18e) columns at different 
flow rates from 1 to 9 ml/min. Mobile phase consist of buffer pH = 2.3: 
acetonitrile in a ratio of (74:26, v/v) and (74.5:25.5, v/v) for conventional and 
monolithic columns, respectively. 
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Figure 27: Plot of the height equivalent to theoretical plate against mobile 
phase flow rate, for pilocarpine, propranolol, glibenclamide and insulin on a 
Chromolith Performance RP-18e column. 
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3.1.2 Results of high speed analysis with flow programming 
3.1.2.1 Optimization of chromatographic parameters 
3.1.2.1.1 Flow rate 
Looking back to the chromatograms of glibenclamide and related products shown in 
Figure 25, the 4 compounds were eluted within 66 seconds at a flow rate of 9 ml/min. 
However, there was a loss of resolution between the peaks of related compounds a 
and b (peaks 1 and 2). In an aim to improve the resolution between compound a and 
compound b at a flow rate of 9 ml/min, the elution strength of the mobile phase was 
modified by decreasing the acetonitrile percentage from 45% to 42%. The resolution 
was improved but the chromatographic run time was increased to about 2.2 min. 
Thus the acetonitrile content was kept at 45%. In order to obtain a complete 
separation between the 4 compounds at the shortest analysis time, a flow program 
was used ranging from 5.0 to 9.9 ml/min to allow a rapid elution of the 4 compounds 
without scarifying resolution. A stepwise increase of the flow rate from 5 to 6 ml/min 
was applied at the first 35 seconds to avoid the loss of resolution between the closely 
related compounds a and b. After that, the flow rate was increased gradually to 9.9 
ml/min to accelerate the elution of the late eluting glibenclamide and glimepiride 
(Table 18).  
Table 18: Flow rate program used during the separation 
 
 
 
 
 
 
The separation was accomplished within 80 seconds. The 4 compounds were well 
separated from each other with a resolution value Rs = 2.2 between the critical peak 
pairs a and b. A representative chromatogram for the fast separation of 
glibenclamide, glimepiride and their two related compounds is shown in Figure 28.   
 
 
 
Time 
(min) 
Flow rate 
(ml/min) 
0.0 5.0 
0.6 6.0 
0.7 9.0 
1.3 9.9 
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Figure 28: Representative chromatograms for related compound a (a) related 
compound b (b), glibenclamide (c) and glimepiride (d) on a Chromolith 
Performance RP-18e column at a flow rate program (5.0 - 9.9 ml/min) and a 
column temperature of 30°C. Mobile phase consist of phosphate buffer pH = 3: 
acetonitrile (55:45, v/v). 
 
 
3.1.2.1.2 Temperature effect 
The temperature of the column oven was set to 30°C because no further 
improvement in peak broadening or decrease in retention times was observed at 
higher temperatures, even when a mobile phase water bath was used in combination 
with the column oven. Temperatures were tested up to 45°C using this flow rate 
program. The effect of temperature was only minor but measurable at the low flow 
rate of 1.25 ml/min at which the retention times for all the 4 peaks was reduced using 
higher temperature. Representative chromatograms of the analyzed mixture at a flow 
rate of 1.25 ml/min using column oven set to 30 °C and to 45 °C are shown in Figure 
29. No change in the resolution or precision was observed with a slight variation in 
buffer pH in the range of 2.5 – 3.5. 
 
 
 
0.48
a 
0.56 
b 
1.07 
c 
1.20 
d 
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3.1.2.2 Method validation 
3.1.2.2.1 Specificity 
The specificity of the method was examined by observing if there was any 
interference from the inactive ingredients. The HPLC chromatograms recorded for 
the inactive ingredients showed no peaks at the retention times of the 4 compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Representative chromatograms for related compound a (a) related 
compound b (b), glibenclamide (c) and glimepiride (d) on a Chromolith 
Performance RP-18e column at a flow rate 1.25 ml/min and a column 
temperature of 30°C for (Chromatogram A), and 45°C for (Chromatogram B). 
Mobile phase consist of buffer pH = 3: acetonitrile (55:45, v/v).   
 
a 
1.92 
b 
2.37 
c 
5.15 
d 
6.05 
Chromatogram A 
Chromatogram B 
b 
2.24 
a 
1.84 
c 
4.88 
d 
5.89 
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3.1.2.2.2 Accuracy 
The accuracy of the method was tested by determination of the recovery using the 
inactive ingredient used in glibenclamide and glimepiride tablet formulations. Good 
recovery percentages were obtained for both glibenclamide and glimepiride. The 
recovery results for both glibenclamide and glimepiride at three concentration levels 
are summarized in Table 19. 
 
Table 19: List of recovery results (n = 10) for glibenclamide and glimepiride 
from synthetic mixture of drug product compounds at three concentration 
levels. 
 
 
3.1.2.2.3 Precision 
To ensure assay precision within day repeatability (n = 5) and between days 
repeatability (n = 5) were assessed at 3 concentration levels for each of the four 
compounds. The RSDs % was found to be < 1.0% for retention time and < 1.2% for 
peak area (Table 20). 
3.1.2.2.4 Linearity 
Calibration curves (peak area vs. concentration) for the four analyzed compounds in 
sample solvent were investigated over a wide concentration range. Results are 
summarized in Table 21. 
3.1.2.2.5 Detection and quantitation limits 
The limit of detection (LOD, S/N = 3) and an estimate for the limit of quantitation 
(LOQ, S/N=10) for the 4 analyzed compounds were also summarized in Table 21. 
 
 
Compound Theoretical 
value (mg/ml) 
Mean recovery 
(mg/ml) 
Recovery % RSD % 
0.16 0.1590 99.34 0.85  
0.20 0.1990 99.95  0.56  glibenclamide  
0.24 0.2409 100.4  0.79  
0.16 0.1603 100.2  0.92  
0.20 0.1988 99.89  0.78  glimepiride 
0.24 0.2370 99.10  1.00  
3 Results 
 
 71 
Table 20: Precision over a concentration range 0.001 - 0.100 mg/ml for related 
compound a and b and 0.01 - 0.24 mg/ml for glibenclamide and glimepiride 
using n=5 for both within day and between days repeatabilities.  
 
 
Compound 
Within day 
repeatability 
RSD range of 
AUC 
Within day 
repeatability 
RSD of tR 
Between day 
repeatability 
RSD range of 
AUC 
Between day 
repeatability 
RSD of tR 
related 
compound a 
0.40% - 0.62% 0.37% 0.58% - 0.79% 0.93% 
related 
compound b 
0.50% - 0.62% 0.80% 0.68% - 1.14% 0.98% 
glibenclamide 
 
0.45% - 0.60% 0.41% 0.76% - 0.85% 0.58% 
glimepiride 
 
0.36% - 0.56% 0.58% 0.63% - 1.03% 0.94% 
 
Table 21: Linearity, detection and quantitation limits of the 4 analyzed 
compounds. 
 
3.1.2.3 Performance parameter  
Peak performance parameters were calculated according to fundamental equations 
(Table 22). The following equations were used to calculate the mentioned 
chromatographic parameters mentioned in Table 22: (N = 16 (tR/w)
2,  asymmetry 
factor (AF) = A/B at 10% of peak height and Resolution Rs  =  2 (tR2-tR1/w2+w1). A 
slow decrease in resolution was observed by applying high flow rates using 
monolithic column. Column efficiency was measured by plotting the plate height (H) 
against the flow rates of the mobile phase. The height equivalent to theoretical plate 
H was calculated from the column length L and theoretical plate N according to 
H = L/N.  
 
Compound 
 
Concentration 
range (mg/ml) 
 
R2 
 
Detection limit 
(µg/ml) 
 
Quantitation 
limit (µg/ml) 
related 
compound a 
0.0002 - 0.1 0.9981 0.048 0.16 
related 
compound b 
0.0002 - 0.1 0.9998 0.050 0.18 
glibenclamide 0.001 - 0.24 0.9998 0.120 0.41 
glimepiride 0.001 - 0.24 0.9981 0.150 0.50 
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Table 22:  Performance parameters for glibenclamide and the two related 
compounds on conventional and monolithic columns.* 
 
Flat curves for plate height versus linear velocity curves were obtained for the four 
analyzed compounds (Figure 30). This indicates that monolithic columns can operate 
at high flow rates with only small decrease in efficiency. The high permeability of the 
monolithic columns was evidenced by a total system back pressure of 253 bar at a 
flow rate of 9.9 ml/min. This high flow rate is not applicable in case of conventional 
particle-packed columns. The backpressure profile during the flow program of 5 to 
9.9 ml/min is shown in Figure 31. This backpressure profile during the flow program 
of 5 to 9.9 ml/min ranged from 144 to 250 bar. 
 
 
Column type 
Theoretical 
plate N (plate 
per column for 
glibenclamide) 
Asymmetry 
factor for 
glibenclamide 
peak 
Resolution 
(Rs) 
compound 
a/compound 
b 
Total run 
time (min) 
Conventional C18 
(flow rate 1.25 ml/min) 
4435 1.8 3.40 11.0 
Monolithic C18 
(flow rate 1.25 ml/min) 
7964 1.0 4.10 6.5 
Monolithic C18 
(flow rate 2 ml/min) 
7540 1.1 3.86 4.5 
Monolithic C18 
(flow rate 3 ml/min) 
6725 1.1 3.20 3.0 
Monolithic C18 
(flow rate 4 ml/min)  
6151 1.0 2.80 2.5 
Monolithic C18 
(flow rate 5 ml/min) 
5807 1.0 2.40 1.8 
Monolithic C18 
(flow rate 6 ml/min) 
5003 1.1 1.90 1.6 
Monolithic C18 
(flow rate 7 ml/min) 
4328 1.0 1.70 1.4 
Monolithic C18 
(flow rate 8 ml/min) 
3755 1.0 1.40 1.3 
Monolithic C18  
(flow rate 9 ml/min) 
2822 1.1 1.13 1.2 
Monolithic C18  
(flow program 5.0 –
 9.9 ml/min) 
5288 1.0 2.20 1.3 
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Figure 30: Van Deemter plot for the 4 analyzed compounds on Chromolith 
Performance column. 
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Figure 31: Backpressure during the flow rate program (5.0 - 9.9 ml/min). Mobile 
phase consist of phosphate buffer pH = 3: acetonitrile (55:45, v/v). 
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A comparison between backpressure on conventional and monolithic columns is 
shown in Figure 32. In conventional columns, the maximum acceptable backpressure 
of 400 bar is reached at a flow rate of about 4 ml/min depending on the column 
length and the mobile phase composition.  
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Figure 32: Plot of column backpressure against flow rate of mobile phase for 
conventional particle-packed (Superspher RP-18e) and monolithic (Chromolith 
Performance RP-18e) columns. Mobile phase consist of phosphate buffer pH = 
3: acetonitrile (55:45, v/v). 
 
3.1.3 Result method development with monolithic columns 
3.1.3.1 Examples for developed methods 
Heir a general strategy is derived for developing a method using monolithic column 
when no previous method on a conventional column is available. The strategy will of 
course depend on the use of high flow rates and the possibility of using flow 
programming offered by monolithic silica columns. 
The steps for RP-HPLC method development using monolithic silica columns have 
been summarized in Chart 2. Examples outlined in this section show how monolithic 
columns can provide fast RP-HPLC method development which would not be 
possible with conventional columns. 
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Chart 2: Strategy for method development using monolithic silica columns. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.3.1.1 Separation of acidic mixture 
The first example shows the separation of seven acidic compounds using monolithic 
silica columns. An initial flow rate of 5 ml/min was used with a mobile phase 
Dissolve the sample in mobile phase or solution of lower strength if possible  
Initial mobile phase phosphate buffer pH 2, 25 mM: acetonitrile (20:80, v/v) 
Equilibrate the column with mobile phase by running at a flow rate of 9 
ml/min for 3 min, and then return to a flow rate of 5 ml/min 
Inject a sample of <25 µl and < 10 µg 
First run high isocratic flow rate 5 ml/min, run time e.g. for 20 min. 
Late eluting peak 
good 
resolution 
Rs > 2 
 
bad 
resolution 
Rs <2 
Increase flow rate by 1 ml/min  
(up to 9 ml/min) in each successive runs to 
decrease run time, but make sure that 
resolution of all peak pairs are more than 2  
Do successive runs with 
reduction of acetonitrile % in 
mobile phase until best 
separation  
Use flow programming 
-Increase mobile phase pH 
 
-Change acetonitrile by  
 methanol or try a mixture of 
 acetonitrile and methanol 
 
-Decrease flow rate or  
 increase column length 
 
-Increase temperature in the 
 range from 25 °C to 45 °C 
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consisting of acetonitrile: phosphate buffer pH 2 (80:20). The chromatogram obtained 
under this condition showed only one peak for the whole mixture indicating a co-
elution of the compounds altogether (Figure 33 a). Successive runs were tried with a 
60%, 40%, 20%, 10% and 5% acetonitrile in the mobile phase.  
0 1 2 3 4 5 6 7 8 9 10 11
Retention Time (min)
0,0
0,2
0,4
0,6
0,8
1,0
1,2
In
te
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it
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Figure 33 a: Separation of seven acidic compounds. Column: Chromolith 
Performance, eluent: Acetonitrile-25mM phosphate buffer pH 2 (80: 20). Flow 
rate: 5ml/min and detection wavelength 273 nm.  Nicotinic acid (1),  resorcin (2), 
phenol(3),  salicylic acid (4), benzoic acid(5), 4-hydroxy-benzoic acid (6) and 2-
Naphthol (7). 
 
The best separation was obtained by 10% acetonitrile but only 5 peaks appeared for 
the 7 compounds because nicotinic acid, resorcin, and phenol co-eluted together 
(Figure 33 b). No further improvement was obtained by decreasing the acetonitrile 
content to 5%. On the other hand, no better separation was obtained by increasing 
the pH to 3, 4, or 5 using acetonitrile as organic modifier. After replacing the best 
obtained ratio of acetonitrile (10%) by methanol (methanol:phosphate pH 2, 10:90), 
also only six peaks appear because the peaks for salicylic and benzoic acids 
overlapped (Figure 33 c).  
1+2+3+4+5+6+7 
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Figure 33 b: Separation of seven acidic compounds. Column: Chromolith 
Performance, eluent: acetonitrile-25mM phosphate buffer pH 2 (10: 90). Flow 
rate: 5ml/min and detection wavelength 273 nm. Nicotinic acid (1),  resorcin (2), 
phenol(3),  salicylic acid (4), benzoic acid(5), 4-hydroxy benzoic acid (6) and 2-
naphthol (7). 
 
 
 
 
 
 
 
 
 
 
Figure 33 c: Separation of seven acidic compounds. Column: Chromolith 
Performance, eluent: methanol-25mM phosphate buffer pH 2 (10: 90). Elution 
order as in Figure 33 b. 
1+2+3 
4 
5
6 
7 
1 
2 
3 
4+5 6 
7 
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The best separation was obtained using pH 3 and 10% methanol in the mobile phase 
(Figure 33 d). Further reduction of the run time was achieved using an appropriate 
flow program of Table 23 as shown in chromatogram of Figure 33 e. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33 d: Separation of seven acidic compounds. Column: Chromolith 
Performance, eluent: methanol:25 mM phosphate buffer pH 3 (10: 90). Flow 
rate: 5ml/min and detection wavelength 273 nm. Peak names as Figure 33 b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33 e: Separation of a seven acidic compounds. Column: Chromolith 
Performance, eluent: methanol-25mM phosphate buffer pH 3 (10: 90) using the 
flow program shown in the Table 23. Peak names as Figure 33 b. 
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Table 23: Flow program used for separation of acidic mixture in Figure 33 e. 
 
 
 
 
 
 
3.1.3.1.2 Separation of aniline and five derivatives 
Figure 34 shows the separation of a basic mixture of aniline and five derivatives. As a 
starting condition a mobile phase of methanol: phosphate buffer pH 2 (80:20) was 
used. Best resolution was obtained after reducing methanol to 45% and increasing 
the pH to 5.  Under this condition the 6 compounds were separated within 4.5 min 
using the flow program mentioned in Table 24.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Separation of six basic compounds aniline and five derivatives. 
Column:Chromolith Performance RP-18e, eluent: phosphate buffer pH 5,  
25 mM: methanol (55:45), detection 214 nm, using the flow program shown in 
Table 24. (1) Aniline (2) N-methylaniline (3) N-ethylaniline (4) 4-ethylaniline (5) 
dimethylaniline (6) N,N-diethylaniline. 
Time (min) Flow rate (ml/min) 
0.0 5 
1.0 6 
1.1 9 
8.0 9 
1 
2 
3 4 5 6 
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Table 24: Flow program used for separation of aniline and its derivatives in 
Figure 34. 
 
Time (min) Flow rate (ml/min) 
0,0 3.0 
2.1 3.0 
2.2 9.0 
5.0 9.0 
 
3.1.3.1.3 Separation of alkaloid mixture 
Figure 35 a shows the separation of a challenging basic alkaloid mixture. This 
chromatogram was the best one obtained after trying several pH values from pH 2 to 
pH 8 in the mobile phase. However, peaks 1, 2 and 3 are still unresolved. Resolution 
of this basic mixture seems to require a high basic pH value in the mobile phase 
which interferes with the column stability.  
 
 
 
 
 
 
 
 
 
 
Figure 35 a: Separation of a basic mixture of seven alkaloids. Column: 
Chromolith Performance Rp-18e, eluent: phosphate buffer 25mM, pH 3: 
methanol (80:20), flow rate: 3 ml/min, detection 214 nm. Compounds are (1) 
codeine phosphate, (2) ephedrine HCL, (3) theophiline ethyendiamine, (4) 
atropine sulfate, (5) yohimbine HCl, (6) butylscopolamine Br, (7) papaverine 
HCl, (6a) butylscopolamine impurity a and (6b) butylscopolamine impurity b. 
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However, as shown in Figure 35 b, a satisfactory separation of peaks 1, 2, 3 has 
been achieved by increasing the separation efficiency through connecting two 
columns together. Although this has doubled the run time in the first place, a 
subsequent reduction in the run time has been achieved again by applying the flow 
program mentioned in Table 25 as shown in the chromatogram of Figure 35 c. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35 b: Separation of a basic mixture of seven alkaloids. Column:two 
connected  Chromolith Performance Rp-18e, eluent: phosphate buffer 25mM, 
pH 3: methanol (80:20), flow rate: 3 ml/min, detection 214 nm. Peak names as in 
Figure 35a. 
 
Table 25: The flow program used for the separation of the basic alkaloid 
mixture of Figure 35c. 
 
Time (min) Flow rate (ml/min) 
0.0 3.0 
3.5 3.0 
5.0 5.0 
5.1 9.0 
18 9.0 
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Figure 35 c: Separation of a basic mixture of seven alkaloids. Column: two 
connected Chromolith Performance Rp-18e, eluent: phosphate buffer 25mM, 
pH 3: methanol (80:20), using the flow program mentioned in Table 25, 
detection 214 nm. Peak names as in Figure 35a. 
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3.2 Enantiomeric separation screening results  
In this work, a methods screening strategy using a set of structurally different 
cyclodextrins has been applied for enantiomeric separation of various enantiomeric 
basic drugs. Ten basic enantiomeric compounds have been selected for this 
screening in the bases of availability and include: atenolol hydrochloride, alprenolol 
hydrochloride, ephedrine hydrochloride, isoprenaline hydrochloride, methadone 
hydrochloride, pindolol hydrochloride, promethazine hydrochloride, propranolol 
hydrochloride, tryptophan, and verapamil hydrochloride. Structures for these tested 
compounds are given in Figure 36. The method employed the use of a low pH 
phosphate buffer (pH 2.5). The use of this low pH buffer value has been reported in 
previous screening strategies [77, 78] and is especially successful for basic 
enantiomeric drugs as they will be ionized under this acidic condition, thus aiding the 
solubility and electrophoretic mobility. Seventeen different cyclodextrins have been 
used in this screening including the three native (α, β, and γ) and derivatized 
cyclodextrin whether uncharged as hydroxypropyl cyclodextrins or negatively 
charged as high sulphated, phosphated, carboxymethylated, and succinylated 
cyclodextrin derivatives. Table 26 and 27 list the screening results for the ten basic 
racemic drugs using these seventeen different cyclodextrins under different 
separation modes (normal and reversed polarity). The corresponding resolution value 
for each successful separation has been calculated. Typical electropherograms 
obtained for the partial or full successful separation of each drug are shown below in 
Figures 37-50. 
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Figure 36: Structure of the ten basic enantiomeric drugs used in this CE 
screening (pri refers to isopropane). 
 
atenolol hydrochloride alprenolol hydrochloride ephedrine hydrochloride 
isoprenaline hydrochloride methadone hydrochloride pindolol hydrochloride 
promethazine hydrochloride propranolol hydrochloride tryptophan  
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HCL HCL 
HCL 
HCL 
HCL 
HCL HCL 
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Table 26: Screening result for atenolol, alprenolol, ephedrine, isoprenaline and 
methadone using different cyclodextrins. 
 
(+) refers to separation under normal polarity 
(-) refers to separation under reversed polarity 
 
 
CD Type Atenolol Alprenolol Ephedrine Isoprenaline Methadone 
α-CD 
One Peak 
(+) 
No Peak No Peak No Peak No Peak 
β-CD No Peak No Peak No Peak No Peak No Peak 
γ-CD No Peak No Peak No Peak No Peak No Peak 
HP-α-CD No Peak No Peak No Peak No Peak One Peak (+) 
HP-β-CD 
(Supelco) 
No Peak No Peak No Peak No Peak 
Two Peaks 
(+) 
HP-β-CD 
(Sigma) 
One Peak 
(+) 
No Peak No Peak Rs = 1.1 (+) 
Two  Peaks 
(+) 
HP-γ-CD No Peak No Peak No Peak Rs = 1.4 (+) No Peak 
CM-β -CD No Peak No Peak No Peak Rs = 1.17 (+) No Peak 
CM-γ-CD No Peak No Peak No Peak Rs = 1.18 (+) No Peak 
HS-α-CD 
Peak with 3 
tops (+) 
Rs = 1.37 (-) 
Rs = 1.53 (-) No Peak No Peak No Peak 
HS-β-CD 
(Supelco) 
Peak with 
two tops 
(+) 
Rs = 0.79 (-) 
Rs = 1.92 (-) 
Peak with 
many 
tops(+) 
No Peak No Peak 
HS-β-CD 
(Sigma) 
Rs = 0.67 (-) 
No Peak(-) 
Two peaks 
one with 2 
tops Rs = 1.4 
Peak with 
two tops (+) 
One Peak (+) 
Rs = 5.74 (-) 
Two Peaks 
(+) 
HS-γ-CD Rs = 2.54 (-) Rs = 1.93 (-) No Peak No Peak No Peak 
Phosphated- 
α-CD 
No Peak 
Two Peaks 
Rs = 0.65(+) 
No Peak No Peak No Peak 
Phosphated- 
β-CD 
No Peak No Peak No Peak No Peak No Peak 
Phosphated- 
γ-CD 
No Peak No Peak No Peak No Peak No Peak 
Succinylated
- β-CD 
No Peak No Peak No Peak No Peak No Peak 
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Table 27: Screening result for pindolol, promethazine, propranolol, tryptophan 
and verapamil using different cyclodextrins. 
 
 
(+) refers to separation under normal polarity 
(-) refers to separation under reversed polarity 
CD Type Pindolol Promethazine Propranolol Tryptophan  Verapamil 
α-CD No Peak No Peak No Peak Rs = 2.45 No Peak 
β-CD No Peak No Peak No Peak No Peak No Peak 
γ-CD No Peak No Peak No Peak No Peak No Peak 
HP-α-CD No Peak No Peak No Peak No Peak 
One Peak 
(+) 
HP-β-CD 
(Supelco) 
No Peak No Peak No Peak No Peak 
Peak with 
shoulder 
(+) 
HP-β-CD 
(Sigma) 
No Peak No Peak No Peak No Peak 
One Peak 
(+) 
HP-γ-CD No Peak No Peak No Peak No Peak 
One Peak 
(+) 
CM-β-CD 
Peak with 
shoulder 
(+) 
No Peak 
Peak with two 
tops (+) 
Rs =  0.4 No Peak 
CM-γ-CD No Peak No Peak 
Bad Peak 
with 2 tops 
(+) 
No Peak No Peak 
HS-α-CD No Peak 
Peak with two 
tops (-) 
No peak (-) No peak Rs = 10.2 (-) 
HS-β-CD 
(Supelco) 
No Peak 
Peak with  
shoulder  (-) 
One Peak (-) No peak Rs = 1.56 (-) 
HS-β-CD 
(Sigma) 
One peak 
top split 
(-) 
No Peak One Peak (-) 
Two Peaks 
one small 
Rs = 7.42 (-) 
HS-γ-CD 
Two bad 
shaped 
peaks (-) 
No Peak One Peak (-) No peak Rs = 6.98 (-) 
Phosphated- 
α-CD 
No Peak No Peak No Peak No peak No Peak 
Phosphated- 
β-CD 
No Peak No Peak No Peak No peak No Peak 
Phosphated- 
γ-CD 
No Peak No Peak No Peak No peak No Peak 
Succinylated- 
β-CD 
No Peak No Peak No Peak No peak 
Peak with 
two tops (+) 
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For atenolol only peaks with two or many tops were obtained under normal polarity 
as shown in Figure 37. Under reversed polarity a better separations were obtained 
ranging from partial to a full base line resolution. However, the best was obtained 
using HS-γ-CD with a resolution value of 2.57 as shown in Figure 38-d. 
 
 
 
 
 
Figure 37: Electropherograms corresponding to the chiral separation of atenolol enantiomers 
in 50 mM phosphate buffer pH (2.5) containing 2% of HS-α-CD in electropherogram (a), and HS-
β-CD (Supelco) in electropherogram (b). Injection by pressure, 50 mbar for 0.3 min; 
temperature 25 
o
C; capillary, 85 cm, (31 cm to the detector x 50 µm ID); applied voltage, 25 kV 
(normal polarity); UV detection at 200 nm.  
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Figure 38: Electropherograms corresponding to the chiral separation of atenolol enantiomers 
in 50 mM phosphate buffer pH (2.5) containing 2% of  HS- α –CD in electropherogram (a),  HS-β-
CD(Supelco)  in electropherogram (b), HS- β -CD (Sigma) in electropherogram (c), and of  HS- γ 
-CD in (d). Applied voltage, -25 kV (reversed polarity). Other conditions were as in legend of 
Figure 37. 
 
For alprenolol normal polarity leads to slight separation (Figure 39). Under reversed 
polarity two cyclodextrins lead to the best similar separation (Figure 40), one using 
HS-β-CD (Supelco) (Rs = 1.93 within about 12 min) and the other using HS-γ-CD (Rs 
= 1.92 within 27 min). It is clear that HS-β-CD (Supelco) will be selected mainly 
because of the shorter run time. 
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   7.51
   7.39
   7.27
   7.15
   7.03
   6.91
   6.79
   6.67
   6.56
   6.44
   6.32
Absorption
26.00 28.00 30.00 32.00 34.00
Time [min]
   7.56
   7.42
   7.28
   7.15
   7.01
   6.87
   6.74
   6.60
   6.46
   6.33
   6.19
Absorption
36.00 38.00 40.00 42.00 44.00 46.00 48.00
Time [min]  
Figure 39: Electropherograms corresponding to the chiral separation of alprenolol enantiomers 
in 50 mM phosphate buffer pH (2.5) containing 2% of HS-β-CD (Sigma) in electropherogram (a), 
and of  phosphated-α-CD in electropherogram (b). Injection by pressure, 50 mbar for 0.3 min; 
temperature 25 
o
C; capillary, 62 cm, (48 cm to the detector x 50 µm ID; applied voltage, 15 kV 
(normal polarity); UV detection at 200 nm.  
 
 
   
 
 
 
Figure 40: Electropherograms corresponding to the chiral separation of alprenolol enantiomers 
in 50 mM phosphate buffer pH (2.5) containing 2% of  HS-α-CD  in electropherogram (a),  HS-β-
CD (Supelco) in electropherogram (b), and of  HS- γ -CD in electropherogram (c). Applied 
voltage -25 kV (reversed polarity). Other conditions were as in legend of Figure 37. 
(a) (b) 
Rs=0.65 
Two peaks one with two tops  
Rs=1.65 
(c) 
Rs=1.93 
Time [min] 
(a) (b) 
Rs=1.53 Rs=1.92 
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Absorption Absorption 
Absorption 
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Ephedrine has two chiral centers and so four enantiomers were expected in the 
product. Unfortunately, the separation was not achieved with any of the tested 
cyclodextrins under normal and reversed polarity. The only slight separations were 
obtained using HS-β-CD from Sigma and from Supelco under normal polarity as 
shown in Figure 41.  
 
 
  10.52
  10.12
   9.72
   9.33
   8.93
   8.53
   8.14
   7.74
   7.34
   6.95
   6.55
Absorption
6.00 8.00 10.00 12.00
Time [min]
  13.94
  13.28
  12.63
  11.97
  11.32
  10.66
  10.01
   9.35
   8.69
   8.04
   7.38
Absorption
4.00 6.00 8.00 10.00
Time [min]  
Figure 41: Electropherograms corresponding to the chiral separation of ephedrine enantiomers 
in 50 mM phosphate buffer pH (2.5) containing 2% of  HS-β-CD (Supelco) in electropherogram 
(a), and of  HS-β-CD (Sigma) in electropherogram (b). Applied voltage 15 kV (normal polarity). 
Other conditions were as in legend of Figure 37. 
 
 
For isoprenaline no separation was achieved with any of the seventeen tested 
cyclodextrins under normal polarity. Under reversed polarity five different 
cyclodextrins gave different degrees of enantiomeric separation as shown in Figure 
42. The best separation was that obtained using HS-β-CD (Supelco), at which the 
two isoprenaline enantiomers were separated within 14 min., with a resolution value 
of 5.74.  
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Figure 42: Electropherograms corresponding to the chiral separation of isoprenaline 
enantiomers in 50 mM phosphate buffer pH (2.5) containing 2% of HS-β-CD (Supelco) in (a) HP-
β-CD (Sigma) in (b), HP-γ-CD in (c), CM-β-CD in (d), CM-γ-CD in (e). Applied voltage -25 kV 
(reversed  polarity). Other conditions were as in legend of Figure 37. 
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In the presence of HS-β-CD from Sigma and under normal polarity two peaks were 
obtained for methadone (Figure 43). However, the second peak is too small in 
comparable with the first peak and so the separation is doubtful and require peak 
identification by using the standard individual enantiomers. 
 
 
 
 
Figure 43: Electropherograms corresponding to the chiral separation of methadone 
enantiomers in 50 mM phosphate buffer pH (2.5) containing 2% of HS-β-CD (Sigma).  Applied 
voltage15 kV (normal polarity). Other conditions were as in legend of Figure 39. 
 
For pindolol a peak with shoulder has been obtained using CM-β-CD under normal 
polarity. This indicates a slight beginning of separation (Figure 44). While under 
reversed polarity the best obtained result was with HS-γ-CD were two bad shape 
peaks have been obtained as shown in Figure 45, however this is still considered as 
a poor initial conditions and should require intensive method optimization. 
 
Figure 44: Electropherograms corresponding to the chiral separation of pindolol enantiomers 
in 50 mM phosphate buffer pH (2.5) containing 2% of CM-β-CD. Applied voltage, 10 kV (normal 
polarity polarity). Other conditions were as in legend of Figure 37. 
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Figure 45: Electropherograms corresponding to the chiral separation of pindolol enantiomers 
in 50 mM phosphate buffer pH (2.5) containing 2% of  HS-β-CD (Sigma) in electropherogram (a), 
and of  HS-γ-CD in (b). Applied voltage, -25kV (reversed polarity). Other conditions were as in 
legend of Figure 37. 
 
In the presence of HS-α-CD and under reversed polarity a peak with two tops was 
obtained for promethazine within a relatively short analysis time as shown in 
Figure 46-a.  
    
Figure 46: Electropherograms corresponding to the chiral separation of promethazine 
enantiomers in 50 mM phosphate buffer pH (2.5) containing 2% of HS-α-CD in 
electropherogram (a), and of HS-β-CD (Supelco) in (b). Applied voltage, -25kV (reversed 
polarity). Other conditions were as in legend of Figure 37. 
 
For propranolol no separation was obtained with any of the cyclodextrin under 
reversed polarity. Applying the normal polarity slight separations that involve peaks 
with shoulders were obtained with CM-β-CD and CM-γ-CD (Figure 47), however the 
better peak shape was that obtained with the CM-β-CD and so will be the one 
selected as initial separation condition. As can be seen in Figure 48, good baseline 
separation was obtained for tryptophan with both α-CD and CM-β-CD. However, the 
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best resolution value was obtained with the native cyclodextrin α-CD that achieved a 
resolution value of 2.45 and in a total analysis time of about 25 min. 
 
Figure 47: Electropherograms corresponding to the chiral separation of propranolol 
enantiomers in 50 mM phosphate buffer pH (2.5) containing 2% of  CM-β-CD in 
electropherogram (a), and of  CM-γ-CD in electropherogram (b). Applied voltage, 10 kV (normal 
polarity).  Other conditions were as in legend of Figure 37. 
 
 
 
 
Figure 48: Electropherograms corresponding to the chiral separation of tryptophan 
enantiomers in 50 mM phosphate buffer pH (2.5) containing 2% of  α-CD in electropherogram 
(a) and (b), and of  CM-β-CD in electropherogram (c), and of  HS-β-CD (Sigma) in 
electropherogram (d). Applied voltage, 10 kV (normal polarity). Other conditions were as in 
legend of Figure 37. 
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Under normal polarity slight separation mainly peak with shoulder was obtained for 
verapamil using HP-β-CD from Supelco (Figure 49). On the other hand, four sets of 
suitable initial conditions were obtained for verapamil under reversed polarity 
(Figure 50). High resolution was achieved using HS-α-CD, HS-β-CD (Sigma) and HS-
γ-CD. The best overall resolution for verapamil (Rs = 10.19) was achieved by HS-α-
CD within a total migration time of about 23 min. The use of HS-β-CD (Sigma) gave a 
lower resolution within the same migration time (Rs = 7.42). However HS-γ-CD gave 
a resolution of (Rs = 6.98) but within a shorter time of 15 min. Then, the choice of the 
best cyclodextrin for the separation of verapamil will depend on which is more 
important for the analysis goal, time or high resolution. Short analysis time is more 
important when the method is intended for the separation and/or quantitation of 
individual enantiomers when they present in a comparable concentrations. The short 
time will then be more suitable for a series of runs in the automated instruments to 
save the analysis time. However, if the method is intended to be used for trace 
enantiomer (enantiomeric impurity determination) then it is more important to have a 
high resolution than to look to the analysis time. The high resolution will prevent the 
peaks overlap between the main enantiomers and impurity enantiomer. This 
becomes clearly important when sample volume or mass overload is used in order to 
reach a lower limit of quantitation for the impurity peak. 
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Figure 49: Electropherograms corresponding to the chiral separation of verapamil enantiomers 
in 50 mM phosphate buffer pH (2.5) containing 2% of  HP-β-CD (Supelco) in electropherogram 
(a), and of HP-β-CD (Sigma) in electropherogram (b). Applied voltage, 25 kV (normal polarity). 
Other conditions were as in legend of Figure 39. 
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Figure 50: Electropherograms corresponding to the chiral separation of verapamil enantiomers 
in 50 mM phosphate buffer pH (2.5) containing 2% of  HS-α-CD in electropherogram (a), and of 
HS-β-CD (Supelco) in electropherogram (b), and of HS-β-CD (Sigma) in electropherogram (c), 
and of  HS-γ-CD in electropherogram (d). Applied voltage, -25 kV (reversed polarity).  Other 
conditions were as in legend of Figure 37. 
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4. Discussion  
4.1 HPLC part 
4.1.1 Transferred methods  
Precision was slightly better on monolithic columns than on the conventional columns 
possibly due to the better peak shape and reduced baseline noise that leads to more 
precise integration. The selected methods include different ratios of organic modifier 
in the mobile phase: 2% in the pilocarpine method, 26% in the insulin method, 45% in 
the glibenclamide method and 60% in the propranolol method. This will probably give 
a more representative evaluation of precision. Because repeatability could be 
affected by the percentage of organic modifier in the mobile phase, but this was not 
found in this study. When higher flow rates were applied on monolithic columns there 
was some loss in resolution. A flow rate of 4 ml/min was selected for precision 
studies, as it provides the smallest analysis time with a baseline resolution (Rs values 
higher than 2) for all investigated methods. 
Methods for the small drug molecules pilocarpine, propranolol, glibenclamide and 
glimepiride with their degradation compounds or related products were successfully 
transferred without any modification. For insulin, optimizing selectivity by slightly 
decreasing the percentage of organic modifier in the mobile phase was sufficient for 
a good resolution on the monolithic column. The tiny decrease of organic modifier 
has a dramatic effect on the retention time of insulin (more than doubling them) and 
desamido-insulin whereas the retention times of the small molecules phenol and 
cresol were kept nearly unchanged. It is not clear why the insulin method was not 
successfully transferred from the conventional particle-packed to the monolithic 
column under the same chromatographic conditions. However, one must keep in 
mind that the mechanism by which polypeptides interact with the reversed-phase 
surface is a bit different as that for small drug molecules. The separation of small 
molecules involves continuous partitioning of the molecules between the mobile 
phase and the hydrophobic stationary phase. Polypeptides, however, are too large to 
completely partition into the hydrophobic phase; possibly they adsorb to the 
hydrophobic surface after entering the column. They then desorb and interact only 
slightly with the surface as they elute down the column. Based on this mechanism, 
the improved mass transfer of monolithic over conventional columns will highly 
accelerate the elution of polypeptides after desorption.  
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Peak tailing with monolithic columns was reported in some previously mentioned 
studies [79, 80]. However, in many other works with monolithic columns a minimal or 
no peak tailing was reported [81-83]. In fact, peak tailing in reversed phase HPLC is 
particularly prevalent when separating basic compounds. It causes a number of 
problems including lower resolution, reduced sensitivity and poor precision and 
quantitation. There are many reasons for peak tailing including injecting sample in a 
solvent that is significantly stronger than the mobile phase, sample mass overload 
and a void in the column packing bed. However, the common cause of peak tailing in 
reversed phase HPLC is the secondary retention. This occurs when an ion-exchange 
interaction takes place between a positively charged solute (ammonium) and an 
acidic silanol on the surface of the silica stationary phase support particles. It is 
observed most often when using HPLC columns packed with stationary phases that 
have significant silanol activity. It is usually worse at neutral pH (6 - 8) than at acidic 
pH (< 3). The less the silanol activity the stationary phase exhibits the less the peak 
tailing. In our investigations all the tested methods were successfully done using a 
mobile phase buffer in the acidic range (pH around 3) therefore no strong tailing was 
observed.  
As expected, the total analysis time was reduced to about a quarter at a flow rate of 4 
ml/min using monolithic columns. A diagram for the percent reduction in analysis time 
for successfully transferred methods from conventional to monolithic columns is 
shown in Figure 51.  
The lower limits of detection and quantitation obtained by the monolithic columns are 
partly due to the lower background noise obtained with these columns. In this 
evaluation of monolithic Chromolith Performance columns the polypeptide insulin was 
also investigated. Larger molecular weight proteins were not investigated because 
the applicability of reversed phase silica for the quantitation of large molecular weight 
portions suffers from the problem of adsorption and the loss of results repeatability. 
Few papers were found in the literature suggesting reversed phase chromatography 
for the quantitation of proteins [84-86]. Furthermore, silica based monolithic columns 
are particularly suited for the separation of small molecules, such as drug candidates 
and peptides, while the polymer monolith are generally preferable for larger 
molecules such as proteins, nucleic acid, and synthetic polymers. In a comparison 
between conventional high performance liquid chromatography (HPLC) and ultra 
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performance liquid chromatography (UPLC) carried out by the Water Company, they 
have reported the solvent consumption as a disadvantage of using monolithic 
columns [87]. 
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Figure 51: Reduction in total run time for the three successfully transferred 
methods. 
 
 
According to our work, the increase in solvent consumption of monolithic columns at 
high flow rates was totally compensated by the decrease in the chromatographic run 
time (Figure 52). The high permeability of the monolithic columns was evidenced by a 
flow rate of 9 ml/min generating a total system back pressure of less than 240 bar in 
all of the four tested methods. In comparison, the conventional column packed with 
4 µm particles, reached a maximum backpressure of about 400 bar when it was 
operated at a flow-rate of 3.5 or 4 ml/min depending on the composition of the used 
mobile phase (Figure 53).  
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Figure 52: Comparison between Superspher and Chromolith performance 
columns in mobile phase consumption, during the run time for the three 
successfully transferred methods.  
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Figure 53: Plot of system backpressure against flow rate for the three 
successfully transferred methods. Pilocarpine (squares), propranolol 
(triangles) and glibenclamide & glimepiride (circles). Closed and open signs 
refer to values on conventional and monolithic columns, respectively. 
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At a flow rate of 1 ml/min backpressure is about five times smaller on a monolithic 
(Chromolith Performance RP-18e) column than on a conventional (Superspher RP 
18e) column (Figure 54). 
Flat curves were obtained for plate height against the flow rates of mobile phases for 
the four tested methods. This indicates that monolithic columns can be operated at 
high flow rates with only small decrease in efficiency. The separations on monolithic 
columns were performed with shorter run time, better peak symmetry and the same 
or better resolution compared to the conventional column, under the same 
chromatographic conditions.  In a conventional Superspher column more time was 
required to re-equilibrate or to wash the stationary phase at a flow of 1ml/min 
(approximately 30 min). 
 
Figure 54: Reduction in system backpressure for the three successfully 
transferred methods from Superspher to Chromolith Performance columns 
under the same flow rate. 
In contrast, the time required to re-equilibrate or wash the monolithic columns until a 
smooth baseline is obtained was 6 times shorter (re-equilibrium time was about 5 min 
at a flow of 6 ml/min) due to the higher flow rates which have been used for 
equilibrium. These favourable flow rates are possible using monolithic silica with its 
typical structure and distribution of mesopores.  
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4.1.2 High speed analysis with flow programming 
An important parameter to be considered in a chromatographic separation is the 
duration of the analysis. Accordingly, fast HPLC methods are important to improve 
productivity e.g. in pharmaceutical analysis. This work presents a fast method for 
simultaneous separation and determination of glimepiride, glibenclamide and two 
related substances by reversed phase liquid chromatography. The data presented 
demonstrates explicit advantages of monolithic columns for the fast HPLC analysis of 
drugs. 
The application of high velocity isocratic elution with monolithic column was limited by 
the loss of resolution between the closely related peaks of related products a and b 
(see Figure 25). In such cases, further reduction in chromatographic run time could 
be achieved by the application of gradient elution of mobile phase or flow rate 
programming. In gradient elution, the solvent polarity (composition) is continuously 
varied or stepped. Two high pressure liquid pumps and a system for mixing and 
degassing the mobile phase must be used. Furthermore, the HPLC gradient mixers 
must provide a very precise control of solvent composition to maintain a reproducible 
gradient profile. The use of flow rate gradient (flow-rate programming) in HPLC 
separations involves a stepwise increase in the flow rate using one pump according 
to a defined flow program. As an important advantage of flow rate program over 
gradient elution of mobile phase, equilibration of the system is not required after each 
separation [88-96]. This is important to achieve fast analysis of a series of samples. 
Flow rate programming is more suitable for monolithic than conventional particle-
packed columns due to higher permeability and lower backpressure. Instrumentation 
failure due to high column back pressure usually occurs when flow programming is 
applied on conventional particle-packed columns [97, 98]. The use of flow program-
ming eliminates the need of re-equilibrium time between successive runs which is 
required in case of mobile phase gradient. The 4 peaks were eluted within less than 
80 second showing that the method can be used as an efficient rapid method for 
series drug analysis.   
Usually, the increase in column temperature in reversed phase HPLC leads to a 
decrease in peak broadening and retention time [99-101]. Accordingly high column 
temperature in combination with a flow program seems to be promising for significant 
reduction in analysis time. Results showed that the application of high column 
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temperature in combination with flow programming in monolithic column did not lead 
to an additional reduction in analysis time. 
Even though, conventional and monolithic silica columns are stable over a similar 
temperature range up to 45°C. Increasing temperature is problematic with monolithic 
columns because they are packed in insulating PEEK [poly(ether ethyl ketone)], 
indicating the importance of applying other type of heating in the column oven.  
RSD% of the interday and the intraday repeatabilities for both retention times and 
peak areas for the four analyzed compounds were less than 1.2%. The method 
showed good linearity and recovery. The short analysis time makes the method very 
valuable for quality control and stability testing of drugs and their pharmaceutical 
preparations. 
4.1.3 Method development  
The parameters that control separation in monolithic silica columns are the same for 
conventional silica columns and for reversed phase HPLC separation in general. 
However the effect of certain parameters on the separation may differ. For example 
parameters as flow rate play a more important role in monolithic silica columns than 
in conventional particle packed columns. On the other hand, parameters as organic 
modifier or pH of the mobile phase play nearly the same role for the two column 
types.  
Flow rate is an important separation parameter that makes a great difference 
between method development on conventional and monolithic silica columns. The 
high permeability offered by the high porosity of the column allows the use of high 
flow rates without the development of a significant backpressure. A standard LC 
method can be converted to a fast LC method on monolithic columns, only by 
increasing the flow rate. In monolithic columns, the increase in flow rate does not 
lead to substantial losses in resolution because of the low mass transfer resistance 
compared to conventional particle-packed columns (See Figure 27 section 3.1.1.3 for 
plate height). This provides a time saving method with minimal loss of resolution. The 
reduction in analysis time could be achieved either by applying a high isocratic flow 
rate or using flow rate programming.  
Monolithic RP-18e column has been used as a stationary phase which is an 
important parameter to affect separation. However, it was still possible to change the 
column length by connecting several columns together using a column coupler. Due 
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to the high column porosity the added column backpressure was still acceptable and 
the prolonged analysis time was compensated by flow programming. Increasing 
column length was particularly important for complex basic mixtures. Usually these 
require the use of high pH mobile phases which is not suitable with silica columns.  
As with conventional columns, decreasing the percentage of organic modifier will 
decrease the elution strength, increase the retention time and improve resolution. 
Acetonitrile and methanol have been selected as the first choice organic modifiers. 
Tetrahydrofuran (THF) which is a possible solvent in reversed phase chromatography 
has been avoided due to its incompatibility with the long term use with PEEK tubing 
of the monolithic column in addition to its well known disadvantages as high 
absorbance and reactivity with oxygen.  
Even though, too much water in the mobile phase can collapse the bonded phase, 
we have obtained a reliable separation for pilocarpine analysis on monolithic column 
with as little as 2% methanol in the mobile phase (See Figure 23 section 3.1.1.3 for 
pilocarpine chromatograms). 
As for conventional silica columns, the pH stability range for monolithic columns 
range from pH 2.0 to pH 7.5. For acidic compounds one will probably succeed to 
achieve a full resolution between the individual compounds using an acidic mobile 
phase. They will be unionized at pH 2 and thus better retained with the possibility to 
obtain the ionizable form for some component by raising the pH in the acidic range to 
improve the selectivity. At pH value of more than ± 1.5 of the pKa the compound will 
be either almost completely ionized or unionized [102]. 
 For basic compounds it is also better to achieve separation in the acidic or mild pH 
ranges because of two reasons: first, because the silica backbone is soluble at high 
pH value. Second reason is to decrease secondary interaction between basic 
compounds and ionized silanol groups of the silica column which leads to extensive 
peak tailing. This effect is minimized at acidic pH at which silanols are nonionized.  
However, some basic compounds have high pKa value (as some alkaloids), it could 
be difficult to obtain full resolution between the individual components without using a 
high pH mobile phase, which is in turn problematic with silica based RP-18 columns 
for the above discussed reasons. In this case it might be an advantageous strategy to 
skip back to mild pH conditions and to improve only a partial separation of peaks by 
column coupling. The increase in column length will gain better resolution. The 
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increased run time due to increased column length could then be reduced by 
applying a proper flow rate program.  
Increasing temperature decreases retention time and band spacing. However, this 
effect is small, and furthermore is greater on ionic than on neutral samples. At least it 
is better to work under constant temperature to maintain constant retention and 
resolution especially for ionic samples [102]. Conventional and monolithic columns 
are stable over the same temperature range up to 45 °C. However, it is not possible 
to use high temperature with monolithic columns as they are insulated with the 
packing material of PEEK [Poly (ether ethyl ketone)]. To overcome this problem, the 
mobile phase should be heated in a water bath and mobile phase lines covered with 
insulator. At the same time a stainless steel capillary connected to the column inlet 
should be placed with the column in the oven. This will insure a certain temperature 
inside the column in spite of the insulating column tube. Furthermore, other heating 
strategies as using microwaves could be tried in column ovens. 
In addition to the above discussed parameters, having a high porosity and low back 
pressure offer the advantages for decreasing washing and re-equilibrium times for 
monolithic columns during method development. This could be done by applying high 
flow rates for re-equilibrium and washing up to 9 ml/min for 3 minutes (See also Chart 
2 section 3.1.3.1). Furthermore this provides less care about the column blockage by 
contaminants. Because of the density of monolithic columns is much lower, the 
loadability of a conventional column of the same size is much higher [103]. 
Accordingly, one should take care not to inject a too large sample weight or volume 
as it is possible for the mass of the sample to overload the column.  
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4.2 Enantiomeric separation discussion 
Method development in chiral separation is complicated because of the many chiral 
selectors available. A simple separation strategy has been used for the rapid 
screening of basic enantiomeric drugs. The aim was the rapid evaluation of the best 
cyclodextrin for the separation of each of the ten basic enantiomeric drugs. An acidic 
phosphate buffer pH 2.5 100 mM has been used to have the basic enantiomers in the 
ionized form as positively charged species. This will probably provide more 
interaction with CD specially the negatively charged one. However, the buffer 
concentration was then reduced from 100 to 50 mM to reduce the current and so the 
capillary temperature specially because the addition of ionic CDs to the buffer 
solution increases the current intensity and it is recommendable to work at low 
current intensities (< 100 µA). 
Screening was started with the native neutral CDs. Experiments showed that the fast 
majority of successful separations have been achieved with the negatively charged 
cyclodextrins under reversed polarity. Under reversed polarity mode the anode is at 
the outlet (in contrast to normal polarity mode), keeping in mind the conditions of 
suppressed electro-osmotic flow (due to the acidic buffer pH 2.5) the negatively 
charged cyclodextrins have strong electrophoretic mobility toward the positive 
electrode (anode). If the enantiomers interact with these negatively charged 
cyclodextrins, they will be swept toward the anode regardless of charge state. Now 
keeping in mind also that the enantiomers of the basic drugs are positively charged 
under this low pH buffer they are more likely to interact with this negatively charged 
cyclodextrin and then the cyclodextrin drug complex will be attracted toward the 
anode at the outlet and pass the detection window. Figure 55 shows representative 
schemes for the mechanism of separation of basic enantiomeric drugs inside the 
capillary using negatively charged cyclodextrin under suppressed EOF by low pH 
value in normal and reversed polarity modes. While neutral compounds interact 
normally with the hydrophobic cavity of this negatively charged cyclodextrin, these 
basic compounds will be strong cations at low pH interacting both with the 
hydrophobic cavity and ionically with the negatively charged groups of the 
cyclodextrin. Identification of individual enantiomers peaks after separation has been 
done before method optimization using standard pure enantiomers. It has been noted 
that the same type of derivatized cyclodextrin from different commercial source gave 
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a different separation result under the same conditions. For example in Figure 38 HS-
β-CD from Supelco gave better resolution for the separation of atenolol than HS-β-
CD from Sigma (Rs value = 0.79 using HS-β-CD from Supelco compared to Rs 
value = 0.67 using HS-β-CD from Sigma). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55: Schematic representation of basic enantiomers separation using 
acidic phosphate buffer pH 2.5 under normal polarity (a) and reversed polarity 
(b). (A+ = ionized basic analyte) 
 
For verapamil HS-β-CD from Sigma gave a resolution Rs value = 7.42 compared to a 
resolution of Rs value = 1.56 using HS-β-CD from Supelco under the same conditions 
(Figure 50). For Ephedrine HS-β-CD from Supelco gave a peak with many tops while 
HS-β-CD from Sigma gave a peak with two tops (Figure 41). Another commercial 
source difference was noted in HP-β-CD, example is shown in Figure 49 for the 
separation of verapamil enantiomers were HP-β-CD from Supelco gave a peak with 
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shoulder while that from Sigma gave only one peak under the same conditions. 
These differences between the separation tendencies of a certain derivatized 
cyclodextrin when obtained from different commercial sources could be attributed to 
difference in derivatization degree so difference in quality. This difference in 
derivatization degree could also be noted to a lesser extend when different batches 
from the same commercial company are used were the reproducibility of the 
separation could also differ.  
Changing the type of cyclodextrin not only affects the separation of the two 
enantiomers but could also invert the migration order when used under the same 
electrophoretic conditions. Figure 48 (b) and (c) show the separation of L and D 
tryptophan using either α-CD as in (b) or CM-β-CD as in (c). Under the same 
separation condition L migrate first when α-CD was used and migrate behind D when 
CM-β-CD was used. This inversion of migration order could be important for 
enantiomeric impurity determination, were it is preferably to have the impurity peak in 
front of the peak of the main enantiomer as they are less likely to overlap and should 
have better resolution. In contrast when the peak of the impurity migrate behind the 
peak of the main enantiomer (in the tail of the peak of the main enantiomer) they are 
more likely to overlap and will probably have a lower resolution value. Whenever the 
neutral and charged cyclodextrin gave a comparable separation, neutral CD will be 
selected as it is the cheaper one and has more defined quality.  
The best results for the screening of each enantiomeric drug are listed in Table 28 
and will be used as a starting point for the optimization process. A 5 mM phosphate 
buffer pH 2.5 (10 folds dilution of the running buffer) has been used as a sample 
solvent to allow the solubility of the basic enantiomers and provide the required 
stacking effect of the sample in the capillary.  A constant voltage in high of 25 kV was 
found to provide the separation in a short time with an acceptable heat production.  
This screening step is the first step for a three steps project that aims to quantitate 
enantiomeric impurities. The screening will be followed by optimization step and 
finally impurity quantitation using the optimized methods. In the screening step all 
cyclodextrins have been used at a nominal concentration of 2 %. The cyclodextrin 
that best resolves the enantiomers should be selected for further optimization. When 
more than one is successful the least expensive cyclodextrin may be the best choice 
keeping in mind good resolution and reasonable analysis time. 
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Table 28: List of the cyclodextrins that lead to the best overall separation 
whether neutral or charged CD under normal or reversed polarity for the ten 
tested basic enantiomeric drugs.   
 
 
Basic 
enantiomeric 
drug 
Best CD for 
separation 
Separation mode Resolution value 
(Rs) 
atenolol HS-γ-CD reversed polarity Rs = 2.54 
alprenolol HS-γ-CD reversed polarity Rs = 1.93 
ephedrine HS-β-CD normal polarity 
peak with 
shoulder 
isoprenaline 
HS-β-CD 
(Sigma) 
reversed polarity Rs = 5.74 
methadone 
HS-β-CD 
(Sigma) 
normal polarity Rs = 4.32 
pindolol HS-γ-CD reversed polarity 
two bad shaped 
peaks 
promethazine HS-α-CD reversed polarity peak with two tops 
propranolol CM-β-CD normal polarity peak with two tops 
tryptophan  α-CD normal polarity Rs = 2.45 
verapamil HS-α-CD reversed polarity Rs = 10.19 
 
For the drugs where no good baseline separation was obtained with any of the tested 
seventeen cyclodextrins, an intensive method optimization should be done using the 
cyclodextrin that gave a beginning of separation (e.g. a peak with shoulder or peak 
with two tops). The optimization will be done by changing certain conditions in order 
to improve the separation in term of resolution and analysis time. It is usually divided 
into primary and secondary optimization. Primary optimization includes the fine-
tuning of the CD concentration in the range of 2 - 20% [104, 105], addition of organic 
modifier to the running buffer (e.g. methanol) [106, 107], changing the buffer pH 
[108], and the use of a mixture of two CDs in a dual system [109, 110]. Furthermore, 
various buffer additives as amines and cellulose derivatives can be employed to 
change the selectivity of the separation by altering electrophoretic mobility [34]. 
Secondary optimization includes variation of ionic strength to enhance stacking and 
increasing the voltage to decrease the migration time.  
The optimized method can then be used to quantitate enantiomeric impurities. As 
stated in the ICH guideline Q6A [111], the impurity in the chiral new drug substance 
should otherwise be treated according to the principles established in the guideline 
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on impurities in new drug substances. Limits of 0.1% enantiomeric impurity are 
widely accepted as threshold in the testing of single enantiomer drug substances 
[112-114]. Thus, enantiomeric separation by CE is important for enantiomeric 
impurity testing. 
The work done so far was for the screening of basic enantiomeric drugs. For acidic 
compounds neutral or cationic cyclodextrin are usually used. Cationic CDs such as 
6-methylamino-β-CD and heptasubstituted methylamino- β-CD have been applied 
for the separation of acidic and neutral compound [115]. For neutral racemats 
neutral cyclodextrins are not applicable due to the formation of neutral complexes 
that do not have electrophoretic motilities. Accordingly the use of charged 
cyclodextrins (whether cationic or anionic) is necessary for the separation of 
neutral racemic drugs. 
Two different CE instruments have been used during this screening process. A 
UniCAM CE instrument which requires a capillary with a total length of 62 cm and an 
effective length (length up to the detector) of 48 cm was used. The effective length of 
48 cm means a relatively long migration time until the analytes reaches the detection 
windows. Of course this is also determined by the migration speed of the analytes 
which is on the other hand controlled by the EOF and the charge to mass ratio of the 
analytes. The outlet of this instrument is fixed and so the outlet vial can not be 
changed automatically between runs. The other instrument PrinCE is a relatively 
modern instrument which requires a capillary with total length of 85 cm but with an 
effective length of only 31 cm. This instrument is characterized by the ability to 
change the outlet during the runs which allow additional facilities as changing the 
buffer outlet automatically after washing with sodium hydroxide before the run to 
avoid changing buffer pH or changing the outlet when running a series of different 
analytes.   
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5. Summary 
5.1 HPLC 
Nowadays, fast HPLC methods are indispensably required to improve productivity in 
pharmaceutical analysis and process analytical technology (PAT). Researchers are 
trying to develop fast LC methods to reduce analysis time without compromising the 
quality of the results. A fast LC method refers to a reduction in total analysis time 
while maintaining the needed resolution, thus offering a greater sample throughput 
and productivity in the analytical laboratory. A possible tool for converting a standard 
LC method to a fast LC method is the use of monolithic silica columns. Due to the 
high permeability of monolithic columns which is provided by the bimodal pore 
structure; high flow rates can be used with acceptable backpressure. Thus, high 
velocity isocratic elution is applicable to accelerate up elution of the analyzed 
compounds and hence reduce the total run time. In monolithic columns, the increase 
in flow rate does not lead to substantial losses in resolution because of the low mass 
transfer resistance compared to conventional particle-packed columns. From our 
studies comparing conventional particle-packed to monolithic silica columns we have 
concluded that methods for the small drug molecules were successfully transferred. 
For the relatively larger molecule insulin, the method was not completely transferred 
from conventional to monolithic column at first go. However, optimization by slightly 
decreasing the percentage of organic modifier in the mobile phase was sufficient for 
a good resolution on the monolithic column. Rapid analytical procedures could be 
obtained when replacing the existing HPLC applications by equivalent ones using 
monolithic columns instead of conventional particulate columns. 
Furthermore, the growing use of such columns requires the definition of a clear 
strategy for method development. Reversed phase HPLC method development 
strategies for conventional columns should be updated to meet the additional 
possibilities of monolithic columns.  
The most important advantages of developing methods with monolithic silica columns 
include the ability to save time for finding initial separation conditions or further 
optimization of selected conditions. This is due to the applicability of high flow rates 
and so shorter run and equilibrium times. Monolithic columns have also shown to be 
advantageous in developing methods for complex mixtures, by connecting two or 
more columns together to increase the separation efficiency. The longer analysis 
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time due to columns connection can then re-decreased by applying a proper flow 
program. Usually, when some compounds of the analyzed mixture have close 
retention time values, while others have not, loss of resolution between the closely 
related peaks limits the ability for further reduction in analysis time. In such cases, 
further reduction in chromatographic run time could be achieved by the application of 
flow rate programming which is only possible by using monolithic columns.  
The use of flow rate gradient (flow-rate programming) in HPLC has an important 
advantage over gradient elution as system equilibration is not required after each 
separation. This is important to achieve fast analysis of a series of samples. 
 
Monolithic columns will be one of the most important tools for efficient analysis in the 
coming years. They will provide excellent and fast analyses with minimal costs using 
the conventional HPLC systems but with minimal mechanical stress. This new trend 
will be highly important for the quality control of drugs. It may be applied for 
processing a large number of samples in a short time, thus being a practical choice 
for routine quality control studies. Furthermore, the newly introduced 3 mm ID C18 
monolithic columns will enable analysts to run samples at a lower flow rates but with 
similar resolution as the 4.6 mm I.D. monolithic columns. This will provide the ability 
to directly couple monolithic columns to mass spectrometers without requiring a post 
column split. Adding the efficiency of monolithic columns to the very high selectivity in 
mass spectrometry will open new possibilities in important fields like proteome 
analysis. Many monolithic stationary phases will be developed in the near future that 
will widen their applicability. 
 
5.2 CE 
CE is a useful addition to the separation techniques available for the resolution and 
quantitation of enantiomers. Particular features of chirally selective CE methods may 
include simplicity, ruggedness, and low cost when compared to the purchase of 
expensive chiral selective HPLC columns. In CE, compared to chromatography, a 
chiral environment can easily be created by filling the capillary with an electrolyte 
solution containing a chiral selector. However, method development for chiral 
separations in CE requires experimental and theoretical training.  
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Initial selections of the best cyclodextrin for the chiral separation of the ten tested 
basic compounds have been done using a proposed screening strategy and based 
on the measured resolution. For the tested compounds satisfactory initial 
enantiomeric separations have been obtained. This approach can also be used to 
test a broad range of chiral compounds including basic and neutral compounds. It 
was observed that negatively charged CDs gave better results compared to the 
neutral CDs. Furthermore, they gave a better enantiomeric separation of the basic 
drugs when applied under reversed polarity due to stronger interaction with the 
positively charged analytes. In general, substituted cyclodextrins are in many cases 
more effective than the native ones in the separation of enantiomers. According to 
recent works high sulphated cyclodextrins are the most efficient ones. However, 
whenever possible neutral CDs are generally preferred because of low cost, more 
defined quality and broad availability. 
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